

10-26-00

A

PATENT APPLICATION

Docket No: 11016US05 / 100-236.P2.C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CONTINUING APPLICATION TRANSMITTAL UNDER 37 CFR §1.53(b)

Box Patent Application

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

This is a request under 37 CFR §1.53 for filing a

- ☒ continuation application.
☐ divisional application.

1. Particulars of Prior Application

Application Serial No: 09/303,828
U.S. Filing Date: May 3, 1999
Title: Improved Therapeutic Compositions Comprising
Bactericidal/Permeability-Increasing (BPI) Protein Products
Art Unit: 1651
Examiner: Naff, D.
Prior Docket No.: 11016US04 / 100-236.P2.C1

CERTIFICATION UNDER 37 CFR §1.10

I hereby certify that this Continuing Application Transmittal Under 37 CFR §1.53(b) and the documents referred to as enclosed therewith are being deposited with the United States Postal Service on October 24, 2000, postage prepaid, in an envelope addressed to BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 utilizing the "Express Mail Post Office to Addressee" service of the United States Postal Service under Mailing Label No. EL542916975US.


Sonji Shivers

2. This request is filed by:

1. Full Name of Inventor	Family Name Lambert, Jr.	First Given Name Lewis	Second Given Name H.
Residence & Citizenship	City Fremont	State or Foreign Country California	Country of Citizenship United States
Post Office Address	Post Office Address 45928 Omega Drive	City Fremont	State & Zip Code/Country California, 94539

2. Full Name of Inventor	Family Name	First Given Name	Second Given Name
Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
Post Office Address	Post Office Address	City	State & Zip Code/Country

3. Full Name of Inventor	Family Name	First Given Name	Second Given Name
Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
Post Office Address	Post Office Address	City	State & Zip Code/Country

- ☐ This application is being filed by less than all the inventors named in the prior application. An accompanying statement requests deletion of the name(s) of the person(s) who are not inventors of the invention being claimed in this application.

3. **Amendments**

- ☒ Amend the first sentence of the specification after "This is" by inserting:
-- a Continuation of U.S. Application No. 09/303,828, filed May 3, 1999 which is
a continuation of U.S. Application No. 08/586,133, filed January 12, 1996,
which is --.
- ☐ Cancel claims in the prior application before calculating the filing fee.
- ☐ A Preliminary Amendment is enclosed.
- ☐ The filing fee is based upon entry of the foregoing amendment(s) (if any).

4. **Copy of Prior Application**

The enclosed is a copy of the prior complete application, including the specification (with claims), drawings, the oath or declaration, and any amendments referred to in the oath or declaration filed to complete the prior application. A Request to Use Computer Readable Form From Another Application with regard to the Sequence Listing is also enclosed.

5. **Incorporation By Reference**

The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under paragraph 4, above, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

6. **Priority**

- ☐ Priority of application No. _____, filed on _____ in
_____ is claimed under 35 USC §119.
- ☐ The certified copy(ies) was(were) filed in prior U.S. application Serial No.
_____.
- ☐ The certified copy(ies) has(have) not been filed.

7. **Assignment**

- ☒ The prior application is assigned of record to XOMA Corporation, and has been recorded at Reel No. 7835, Frame No. 0703 (3 pages).

8. **Small Entity Status**

- ☐ Verified statement(s) claiming small entity status is(are) attached.
- ☐ Small entity status has been established in the prior application and is still proper and desired.

9. Fee Calculation

CLAIMS AS FILED – INCLUDING PRELIMINARY AMENDMENT (IF ANY)						
			SMALL ENTITY		OTHER THAN A SMALL ENTITY	
	NO. FILED	NO. EXTRA	RATE	FEE	RATE	FEE
BASIC FEE				\$355.00		\$710.00
TOTAL	14-20	= 0	X 9 =	\$	X 18 =	\$
INDEP.	4-3	= 1	X 40 =	\$	X 80 =	\$ 80.00
<input type="checkbox"/> First Presentation of Multiple Dependent Claim			+ 135 =	\$	+ 270 =	\$
Filing Fee:				\$	OR	\$790.00

10. Method of Payment of Fees

- ☐ Attached is a check in the amount of: \$ _____
- ☐ Charge Deposit Account No. 13-0017 in the amount of: \$ _____
A copy of this Transmittal is enclosed.
- ☒ This continuation application is being filed without a fee.

11. Deposit Account and Refund Authorization

The Commissioner is hereby authorized to charge any deficiency in the amount enclosed or any additional fees, other than the application filing fee, which may be required during the pendency of this application under 37 CFR §1.16 or 37 CFR §1.17 to Deposit Account No. 13-0017. A copy of this Transmittal is enclosed. Please refund any overpayment to McAndrews, Held & Malloy, Ltd. at the address below.

Please direct all future communications to:

Janet M. McNicholas, Ph.D.
McAndrews, Held & Malloy, Ltd.
500 W. Madison Street, 34th Floor
Chicago, Illinois 60661

Respectfully submitted,

McANDREWS, HELD & MALLOY, Ltd.
 500 W. Madison Street, 34th Floor
 Chicago, Illinois 60661
 (312) 775-8000
 (312) 775-8100 (Telefacsimile)

By: Janet M. McNicholas
 Janet M. McNicholas, Ph.D.
 Reg. No. 32,918

October 24, 2000


SOLE INVENTOR

"EXPRESS MAIL" Mailing Label No.

EL542916975US

Date of Deposit: October 24, 2000.

I hereby certify that this paper (or fee),
postage prepaid, is being deposited with the
United States Postal Service "EXPRESS MAIL
POST OFFICE TO ADDRESSEE" service under
37 CFR §1.10 on the date indicated above
and is addressed to: Assistant Commissioner
for Patents, Washington, D.C. 20231


Sonji Shivers

APPLICATION FOR
UNITED STATES LETTERS PATENT

S P E C I F I C A T I O N

Attorney's Docket No. 11016US05 / 100-236.P2.C2

TO ALL WHOM IT MAY CONCERN:

Be it known that I, LEWIS H. LAMBERT, Jr., a citizen of the United States, residing at 45928 Omega Drive, Fremont, California 94539, a citizen of the United States, have invented new and useful "IMPROVED THERAPEUTIC COMPOSITIONS COMPRISING BACTERICIDAL/PERMEABILITY-INCREASING (BPI) PROTEIN PRODUCTS" of which the following is a specification.

004207 60296960

**IMPROVED THERAPEUTIC COMPOSITIONS COMPRISING
BACTERICIDAL/PERMEABILITY-INCREASING
(BPI) PROTEIN PRODUCTS**

This is a continuation-in-part of U.S. Application Serial No.

- 5 08/530,599 filed September 19, 1995, which is in turn a continuation-in-part of
U.S. Application Serial No. 08/372,104 filed January 13, 1995, all of which are
incorporated herein by reference.

BACKGROUND OF THE INVENTION

- 10 The present invention relates generally to improved therapeutic
compositions and treatment methods utilizing poloxamer (polyoxypropylene-
polyoxyethylene block copolymer) surfactants for enhancing the activity of
bactericidal/permeability-increasing protein (BPI) protein products.

- 15 BPI is a protein isolated from the granules of mammalian
polymorphonuclear leukocytes (PMNs or neutrophils), which are blood cells
essential in the defense against invading microorganisms. Human BPI protein has
been isolated from PMNs by acid extraction combined with either ion exchange
chromatography [Elsbach, *J. Biol. Chem.*, 254:11000 (1979)] or *E. coli* affinity
chromatography [Weiss, et al., *Blood*, 69:652 (1987)]. BPI obtained in such a
manner is referred to herein as natural BPI and has been shown to have potent
20 bactericidal activity against a broad spectrum of gram-negative bacteria. The
molecular weight of human BPI is approximately 55,000 daltons (55 kD). The
amino acid sequence of the entire human BPI protein and the nucleic acid
sequence of DNA encoding the protein have been reported in Figure 1 of Gray et
al., *J. Biol. Chem.*, 264:9505 (1989), incorporated herein by reference. The Gray
25 et al. amino acid sequence is set out in SEQ ID NO: 1 hereto. U.S. Patent No.
5,198,541 discloses recombinant genes encoding and methods for expression of
BPI proteins, including BPI holoprotein and fragments of BPI.

BPI is a strongly cationic protein. The N-terminal half of BPI
accounts for the high net positive charge; the C-terminal half of the molecule has a

09696709-102400

net charge of -3. [Elsbach and Weiss (1981), *supra*.] A proteolytic N-terminal fragment of BPI having a molecular weight of about 25 kD has an amphipathic character, containing alternating hydrophobic and hydrophilic regions. This N-terminal fragment of human BPI possesses the anti-bacterial efficacy of the naturally-derived 55 kD human BPI holoprotein. [Ooi et al., *J. Bio. Chem.*, 262: 14891-14894 (1987)]. In contrast to the N-terminal portion, the C-terminal region of the isolated human BPI protein displays only slightly detectable anti-bacterial activity against gram-negative organisms. [Ooi et al., *J. Exp. Med.*, 174:649 (1991).] An N-terminal BPI fragment of approximately 23 kD, referred to as "rBPI₂₃," has been produced by recombinant means and also retains anti-bacterial activity against gram-negative organisms. Gazzano-Santoro et al., *Infect. Immun.* 60:4754-4761 (1992).

The bactericidal effect of BPI has been reported to be highly specific to gram-negative species, e.g., in Elsbach and Weiss, *Inflammation: Basic Principles and Clinical Correlates*, eds. Gallin et al., Chapter 30, Raven Press, Ltd. (1992). BPI is commonly thought to be non-toxic for other microorganisms, including yeast, and for higher eukaryotic cells. Elsbach and Weiss (1992), *supra*, reported that BPI exhibits anti-bacterial activity towards a broad range of gram-negative bacteria at concentrations as low as 10^{-8} to 10^{-9} M, but that 100- to 1,000-fold higher concentrations of BPI were non-toxic to all of the gram-positive bacterial species, yeasts, and higher eukaryotic cells tested at that time. It was also reported that BPI at a concentration of 10^{-6} M or 160 μ g/ml had no toxic effect, when tested at a pH of either 7.0 or 5.5, on the gram-positive organisms *Staphylococcus aureus* (four strains), *Staphylococcus epidermidis*, *Streptococcus faecalis*, *Bacillus subtilis*, *Micrococcus lysodeikticus*, and *Listeria monocytogenes*. BPI at 10^{-6} M reportedly had no toxic effect on the fungi *Candida albicans* and *Candida parapsilosis* at pH 7.0 or 5.5, and was non-toxic to higher eukaryotic cells such as human, rabbit and sheep red blood cells and several human tumor cell lines. See also Elsbach and Weiss, *Advances in Inflammation Research*, ed. G. Weissmann, Vol. 2, pages 95-113 Raven Press (1981). This

reported target cell specificity was believed to be the result of the strong attraction of BPI for lipopolysaccharide (LPS), which is unique to the outer membrane (or envelope) of gram-negative organisms.

5 The precise mechanism by which BPI kills gram-negative bacteria is not yet completely elucidated, but it is believed that BPI must first bind to the surface of the bacteria through electrostatic and hydrophobic interactions between the cationic BPI protein and negatively charged sites on LPS. LPS has been referred to as "endotoxin" because of the potent inflammatory response that it stimulates, i.e., the release of mediators by host inflammatory cells which may
10 ultimately result in irreversible endotoxic shock. BPI binds to lipid A, reported to be the most toxic and most biologically active component of LPS.

In susceptible gram-negative bacteria, BPI binding is thought to disrupt LPS structure, leading to activation of bacterial enzymes that degrade phospholipids and peptidoglycans, altering the permeability of the cell's outer
15 membrane, and initiating events that ultimately lead to cell death. [Elsbach and Weiss (1992), *supra*]. BPI is thought to act in two stages. The first is a sublethal stage that is characterized by immediate growth arrest, permeabilization of the outer membrane and selective activation of bacterial enzymes that hydrolyze phospholipids and peptidoglycans. Bacteria at this stage can be rescued by growth
20 in serum albumin supplemented media [Mannion et al., *J. Clin. Invest.*, 85:853-860 (1990)]. The second stage, defined by growth inhibition that cannot be reversed by serum albumin, occurs after prolonged exposure of the bacteria to BPI and is characterized by extensive physiologic and structural changes, including apparent damage to the inner cytoplasmic membrane.

25 Initial binding of BPI to LPS leads to organizational changes that probably result from binding to the anionic groups in the KDO region of LPS, which normally stabilize the outer membrane through binding of Mg^{++} and Ca^{++} . Attachment of BPI to the outer membrane of gram-negative bacteria produces rapid permeabilization of the outer membrane to hydrophobic agents such as
30 actinomycin D. Binding of BPI and subsequent gram-negative bacterial killing

09696709-102400

depends, at least in part, upon the LPS polysaccharide chain length, with long O-chain bearing, "smooth" organisms being more resistant to BPI bactericidal effects than short O-chain bearing, "rough" organisms [Weiss et al., *J. Clin. Invest.* 65: 619-628 (1980)]. This first stage of BPI action, permeabilization of the gram-negative outer envelope, is reversible upon dissociation of the BPI, a process requiring the presence of divalent cations and synthesis of new LPS [Weiss et al., *J. Immunol.* 132: 3109-3115 (1984)]. Loss of gram-negative bacterial viability, however, is not reversed by processes which restore the envelope integrity, suggesting that the bactericidal action is mediated by additional lesions induced in the target organism and which may be situated at the cytoplasmic membrane (Mannion et al., *J. Clin. Invest.* 86: 631-641 (1990)). Specific investigation of this possibility has shown that on a molar basis BPI is at least as inhibitory of cytoplasmic membrane vesicle function as polymyxin B (In't Veld et al., *Infection and Immunity* 56: 1203-1208 (1988)) but the exact mechanism as well as the relevance of such vesicles to studies of intact organisms has not yet been elucidated.

BPI is also capable of neutralizing the endotoxic properties of LPS to which it binds. Because of its bactericidal properties for gram-negative organisms and its ability to neutralize LPS, BPI can be utilized for the treatment of mammals suffering from diseases caused by gram-negative bacteria, such as bacteremia or sepsis.

Poloxamer (polyoxypropylene-polyoxyethylene block copolymer) surfactants are non-ionic block copolymer surfactants having a structure composed of two blocks or chains of hydrophilic polyoxyethylene (POE) flanking a single block of hydrophobic polyoxypropylene (POP). They are considered to be among the least toxic of known surfactants and are widely used in foods, drugs and cosmetics.

Of interest to the present invention is co-owned, co-pending allowed U.S. Patent Application Serial No. 08/190,869 (PCT Application Publication No. WO 94/17819), herein incorporated by reference, which describes the improved

solubilization or stability of pharmaceutical compositions containing BPI protein products and a poloxamer surfactant, either alone or in combination with a polysorbate surfactant.

Also of interest to the present invention are PCT Application
5 Publication No. WO88/06038 and U.S. Patent No. 5,183,687, which address use of poloxamer surfactants with and without "conventional" antibiotics in the treatment of viral, *Mycobacterium* and *Coccidioides* infections.

There exists a desire in the art for methods and compositions
capable of improving the therapeutic effectiveness of antibacterial agents such as
10 BPI protein products. Such methods and compositions could ideally reduce the dosage of agent required to achieve desired therapeutic effects.

SUMMARY OF THE INVENTION

The present invention provides improved anti-microbial
compositions and methods of treatment. According to one aspect of the invention,
15 improved therapeutic compositions are provided that comprise a BPI protein product and a polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant that enhances the anti-bacterial activity of the BPI protein product. Presently preferred bactericidal-activity-enhancing poloxamer surfactants include poloxamer 333 (PLURONIC 103, BASF, Parsippany, NJ), poloxamer 334
20 (PLURONIC 104, BASF), poloxamer 335 (PLURONIC 105, BASF), or poloxamer 403 (PLURONIC P123, BASF). Poloxamers employed according to the invention may optionally be heat-treated prior to incorporation into the compositions. Especially preferred are compositions including poloxamer 333 or poloxamer 403. This aspect of the invention is based upon the finding that the
25 combination of a BPI protein product with one of the above-listed poloxamer surfactants unexpectedly enhances the bactericidal activity of the BPI protein product, both *in vitro* and *in vivo*. The improved therapeutic compositions of the present invention may further comprise ethylenediaminetetraacetic acid (EDTA). This aspect of the invention is based on the discovery that the addition of EDTA

004207" 60796960

to therapeutic compositions containing BPI protein product and a bactericidal-activity-enhancing poloxamer surfactant (such as poloxamer 333, poloxamer 334, poloxamer 335 or poloxamer 403) may produce further enhancement of the bactericidal activity of the BPI protein product.

5 Corresponding improved methods for treating bacterial infection are also provided, the improvement comprising administering to a patient with a suspected or confirmed infection a therapeutic composition of BPI protein product and a bactericidal-activity-enhancing poloxamer, and optionally EDTA. The present invention also contemplates the use of a bactericidal-activity-enhancing
10 poloxamer surfactant (such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403) with a BPI protein product, and optionally EDTA, for the manufacture of a medicament for treatment of bacterial infection.

The present invention further provides improved compositions for inhibiting bacterial and fungal growth comprising a BPI protein product and a
15 bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, and optionally EDTA. This aspect of the invention is based upon the discovery that combination of a BPI protein product with a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant unexpectedly enhances the growth-inhibitory activity of the BPI protein product. Corresponding methods of killing or inhibiting
20 the growth of bacteria or fungi are provided that comprise contacting the organisms with a composition comprising a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, and optionally EDTA. Presently preferred bacterial and fungal growth-inhibiting enhancing poloxamer surfactants include poloxamer 333, poloxamer 334, poloxamer 335, and
25 poloxamer 403.

With regard to the improved methods for treating bacterial infection described above, a method of improving the therapeutic effectiveness of antibiotics for treatment of bacterial infections is also provided. According to this method, the antibiotic is concurrently administered with a composition comprising a BPI
30 protein product formulated with a BPI-activity-enhancing poloxamer surfactant

004207" 6029550

(such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403), and optionally with EDTA. This aspect of the invention is based on the discovery that the improvement in therapeutic effectiveness of antibiotics that is seen with the addition of BPI protein product can be further enhanced by various poloxamer
5 formulations, and that the addition of EDTA to the BPI protein product/poloxamer formulation provides an even greater enhancement of the antibiotic's therapeutic effectiveness. This aspect of the invention also provides use of poloxamer surfactants (such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403), optionally with EDTA, for the manufacture of a medicament containing BPI
10 protein product for co-treatment of a bacterial infection with an antibiotic.

The following findings are illustrative of this aspect of the invention: For a *Pseudomonas* species, enhancement of the improved therapeutic effectiveness of ceftizoxime was provided by BPI protein product formulations containing poloxamer 333, poloxamer 335, or poloxamer 403; enhancement for
15 ceftriaxone was provided by BPI protein product formulations containing poloxamer 333, poloxamer 335, or poloxamer 403; and enhancement for chloramphenicol was provided by BPI protein product formulations containing poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403. For an *Acinetobacter* species, enhancement for ceftazidime was provided by BPI protein
20 product formulations containing poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403; enhancement for ceftriaxone was provided by BPI protein product formulations containing poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403; and enhancement for chloramphenicol was provided by BPI protein product formulations containing poloxamer 333, poloxamer 334,
25 poloxamer 335, or poloxamer 403. For a *Streptococcus* species, enhancement for oxacillin was provided by BPI protein product formulations containing poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403. For an *Enterococcus* species, enhancement for rifampicin was provided by BPI protein product formulations containing poloxamer 335 or poloxamer 403; and enhancement for

0969709-104400

ciprofloxacin was provided by BPI protein product formulations containing poloxamer 333.

For a *Pseudomonas* species, enhancement of the therapeutic effectiveness of a variety of antibiotics was provided by a BPI protein product formulation containing poloxamer 403, and even greater enhancement was provided by adding increasing concentrations of EDTA to the BPI/poloxamer 403 formulation.

Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon consideration of the following detailed description of the invention which describes presently preferred embodiments thereof.

DETAILED DESCRIPTION

The present invention provides improved anti-microbial compositions and methods of treatment. The improved methods and compositions, in addition to being useful for treatment of bacterial infections and conditions associated therewith or resulting therefrom (such as sepsis and bacteremia), and are also useful for prophylaxis of patients at high risk of bacterial infection, e.g., patients who will undergo abdominal or genitourinary surgery, or trauma victims.

Specifically, the present invention provides, in a therapeutic composition comprising a BPI protein product and a stabilizing poloxamer surfactant, the improvement comprising a bactericidal-activity-enhancing poloxamer surfactant, such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403. The present invention is based upon the finding that the combination of a BPI protein product with one of these above-listed poloxamer surfactants unexpectedly enhances the bactericidal activity of the BPI protein product, both *in vitro* and *in vivo*. The improved therapeutic compositions of the present invention may further comprise EDTA. This aspect of the invention is based on the discovery that the addition of EDTA to some therapeutic compositions containing BPI protein product and a bactericidal-activity-enhancing

poloxamer surfactant, such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403, produces further enhancement of the bactericidal activity of the BPI protein product. Such compositions may optionally comprise pharmaceutically acceptable diluents, adjuvants or carriers. The invention utilizes any of the large variety of BPI protein products known to the art including natural BPI protein, recombinant BPI protein, BPI fragments, BPI analogs, BPI variants, and BPI peptides.

Corresponding improved methods for treating bacterial infection are also provided, the improvement comprising administering to a patient with a suspected or confirmed infection a therapeutic composition of BPI protein product and a bactericidal-activity-enhancing poloxamer, and optionally EDTA. The present invention also contemplates the use of a bactericidal-activity-enhancing poloxamer surfactant (such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403) with a BPI protein product, and optionally EDTA, for the manufacture of a medicament for treatment of bacterial infection. The therapeutic composition of BPI protein product and poloxamer surfactant with or without EDTA may be administered systemically or topically to a subject suffering from a suspected or confirmed bacterial infection.

Poloxamer 333 is sold by BASF (Parsippany, NJ) under the name PLURONIC P103 and has a molecular weight of 4950 and a hydrophilic/lipophilic balance (HLB) value of 7-12. Poloxamer 334 is sold by BASF under the name PLURONIC P104 and has a molecular weight of 5900 and an HLB value of 12-18. Poloxamer 335 is sold by BASF under the name PLURONIC P105 and has a molecular weight of 6500 and an HLB value of 12-18. Poloxamer 403 is sold by BASF under the name PLURONIC P123 and has a molecular weight of 5750 and an HLB value of 7-12. Presently preferred bactericidal-activity-enhancing poloxamer surfactants include poloxamer 333, poloxamer 334, poloxamer 335 or poloxamer 403. Especially preferred are compositions including poloxamer 333 or poloxamer 403.

Poloxamers employed according to the invention may optionally be heat-treated prior to incorporation into the compositions. A preferred method of heat treatment is as follows: (1) making a solution of the poloxamer in deionized water, (2) heating the solution to a boil, (3) removing it from heat, (4) allowing it to cool to room temperature, and (5) stirring until the poloxamer is completely solubilized. Alternatively, in the heating step (2), the solution may be boiled for up to 30 minutes or more.

The present invention further provides improved compositions for inhibiting bacterial and fungal growth comprising a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, and optionally EDTA. This aspect of the invention is based upon the discovery that a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant unexpectedly enhances the growth-inhibitory activity of BPI protein product, and that improved compositions comprising such poloxamer surfactants and BPI protein product display superior growth-inhibitory preservative effects. Corresponding methods of killing or inhibiting the growth of bacteria or fungi are provided that comprise contacting the organisms with a composition comprising a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, and optionally EDTA. Presently preferred bacterial and fungal growth-inhibiting enhancing poloxamer surfactants include poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

These methods can be practiced *in vivo* or in a variety of *in vitro* uses such as use as a preservative, use to decontaminate fluids and surfaces, or use to sterilize surgical and other medical equipment and implantable devices, including prosthetic joints. These methods can also be used for *in situ* sterilization of indwelling invasive devices such as intravenous lines and catheters which are often foci of infection and in the preparation of growth media for cells. The efficacy of the improved compositions for inhibiting bacterial and fungal growth can be evaluated according to the assay described below in Example 8, or by any of the assays described in co-owned, copending patent application Cohen et al.,

U.S. Serial No. 08/125,651 filed September 22, 1993, and continuation-in-part thereof U.S. Serial No. 08/273,401 filed July 11, 1994, and continuation-in-part thereof U.S. Serial No. 08/311,611 filed September 22, 1994, and corresponding PCT Application No. PCT/US94/11225, and co-owned, copending patent application (Little et al.) U.S. Serial No. 08/183,222 filed January 14, 1994, and continuation-in-part thereof U.S. Serial No. 08/209,762 filed March 11, 1994, and continuation-in-part thereof (Horwitz et al.) U.S. Serial No. 08/274,299 filed July 11, 1994, and continuation-in-part thereof U.S. Serial No. 08/372,783 filed January 13, 1995, and corresponding PCT Application No. PCT/US95/00656, and co-owned, copending patent application Little et al., U.S. Serial No. 08/183,222 filed January 14, 1994, and continuation-in-part thereof U.S. Serial No. 08/209,762 filed March 11, 1994, and continuation-in-part thereof U.S. Serial No. 08/273,540 filed July 11, 1994, and continuation-in-part thereof U.S. Serial No. 08/372,105 filed January 13, 1995, and corresponding PCT Application No. PCT/US95/00498, all of which are incorporated herein by reference.

BPI protein product is thought to interact with a variety of host defense elements present in whole blood or serum, including complement, p15 and LBP, and other cells and components of the immune system. Such interactions may result in potentiation of the activities of BPI protein product. Because of these interactions, BPI protein products can be expected to exert even greater activity *in vivo* than *in vitro*. Thus, while *in vitro* tests are predictive of *in vivo* utility, absence of activity *in vitro* does not necessarily indicate absence of activity *in vivo*. For example, BPI has been observed to display a greater bactericidal effect on gram-negative bacteria in whole blood or plasma assays than in assays using conventional media. [Weiss et al., *J. Clin. Invest.* 90:1122-1130 (1992)]. This is also shown in *in vivo* animal experiments (see, e.g., co-owned, copending U.S. Application Cohen et al., U.S. Serial NO. 08/311,611 filed September 22, 1994, and corresponding PCT Appl. No. PCT/US94/11225, all of which are incorporated herein by reference. This may be because conventional *in vitro* systems lack the blood elements that facilitate or potentiate BPI's function *in vivo*,

or because conventional media contain higher than physiological concentrations of magnesium and calcium, which are typically inhibitors of the anti-bacterial activity of BPI protein products. Furthermore, in the host, BPI protein product is available to neutralize endotoxin released during host infection, including from stress-induced translocation of gram-negative bacteria or from antibiotic treatment of gram-negative bacteria, a further clinical benefit not seen in or predicted by *in vitro* tests.

It is also contemplated that the BPI protein product be administered with other products that potentiate the bactericidal activity of BPI protein products. For example, serum complement potentiates the gram-negative bactericidal activity of BPI protein products; the combination of BPI protein product and serum complement provides synergistic bactericidal/growth inhibitory effects. See, e.g., Ooi *et al. J. Biol. Chem.*, 265: 15956 (1990) and Levy *et al. J. Biol. Chem.*, 268: 6038-6083 (1993) which address naturally-occurring 15 kD proteins potentiating BPI antibacterial activity. See also co-owned, co-pending PCT Application No. US94/07834 filed July 13, 1994, which corresponds to U.S. Patent Application Serial No. 08/274,303 filed July 11, 1994 as a continuation-in-part of U.S. Patent Application Serial No. 08/093,201 filed July 14, 1993. These applications, which are all incorporated herein by reference, describe methods for potentiating gram-negative bactericidal activity of BPI protein products by administering lipopolysaccharide binding protein (LBP) and LBP protein products. LBP protein derivatives and derivative hybrids which lack CD-14 immunostimulatory properties are described in PCT Application No. US94/06931 filed June 17, 1994, which corresponds to co-owned, co-pending U.S. Patent Application Serial No. 08/261,660, filed June 17, 1994 as a continuation-in-part of U.S. Patent Application Serial No. 08/079,510, filed June 17, 1993, the disclosures of all of which are hereby incorporated by reference.

An advantage provided by the present invention is the ability to provide more effective killing or growth inhibition of bacteria and fungi and enhanced anti-bacterial or anti-fungal activity of the BPI protein product.

Therapeutic compositions comprising BPI protein product and a BPI anti-microbial activity enhancing poloxamer surfactant, and optionally containing EDTA, may be administered systemically or topically. Systemic routes of administration include oral, intravenous, intramuscular or subcutaneous injection (including into a depot for long-term release), intraocular and retrobulbar, intrathecal, intraperitoneal (e.g. by intraperitoneal lavage), transpulmonary using aerosolized or nebulized drug, or transdermal. For example, when given parenterally, BPI protein product compositions are generally injected in doses ranging from 1 $\mu\text{g/kg}$ to 100 mg/kg per day, and preferably at doses ranging from 0.1 mg/kg to 20 mg/kg per day. The treatment may continue at the same, reduced or increased dose per day for, e.g., 1 to 3 days, and additionally as determined by the treating physician. Topical routes include administration in the form of salves, ophthalmic drops, ear drops, irrigation fluids (for, e.g., irrigation of wounds) or medicated shampoos. For example, for topical administration in drop form, about 10 to 200 μL of a BPI protein product composition may be applied one or more times per day as determined by the treating physician. Those skilled in the art can readily optimize effective dosages and administration regimens for therapeutic compositions comprising BPI protein product and a BPI bactericidal-activity enhancing poloxamer surfactant, and optionally containing EDTA, as determined by good medical practice and the clinical condition of the individual patient.

With regard to the improved methods for treating bacterial infection described above, a method of improving the therapeutic effectiveness of antibiotics for treatment of bacterial infections is also provided. According to this method, the antibiotic is concurrently administered with a composition comprising a BPI protein product formulated with a BPI-activity-enhancing poloxamer surfactant (such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403), and optionally with EDTA. This aspect of the invention is based on the discovery that the improvement in therapeutic effectiveness of antibiotics that is seen with the addition of BPI protein product can be further enhanced by various poloxamer formulations, and that the addition of EDTA to the BPI protein product/poloxamer

09596709 " 102480
084207" 6029660

formulation provides an even greater enhancement of the antibiotic's therapeutic effectiveness. This aspect of the invention also provides use of poloxamer surfactants (such as poloxamer 333, poloxamer 334, poloxamer 335, or poloxamer 403), optionally with EDTA, for the manufacture of a medicament containing BPI protein product for co-treatment of a bacterial infection with an antibiotic.

For this aspect of the invention, the improved therapeutic effectiveness of antibiotics seen upon concurrent administration with BPI protein product can be observed in a number of ways. For example, a BPI protein product may convert an organism that is clinically resistant to an antibiotic into an organism that is clinically susceptible to the antibiotic, or may otherwise improve the antibiotic susceptibility of that organism. The BPI protein product and antibiotic may have a therapeutic effect when both are given in doses below the amounts sufficient for monotherapeutic effectiveness. The inclusion of a BPI-activity-enhancing poloxamer surfactant in the BPI protein product formulation provides a further enhancement of these activities. Co-owned, copending patent application Cohen et al., U.S. Serial No. 08/125,651 filed September 22, 1993, and continuation-in-part thereof U.S. Serial No. 08/273,401 filed July 11, 1994, and continuation-in-part thereof U.S. Serial No. 08/311,611 filed September 22, 1994, and corresponding PCT Application No. PCT/US94/11225, and co-owned, copending patent application (Little et al.), U.S. Serial No. 08/183,222 filed January 14, 1994, and continuation-in-part thereof U.S. Serial No. 08/209,762 filed March 11, 1994, and continuation-in-part thereof (Horwitz et al.) U.S. Serial No. 08/274,299 filed July 11, 1994, and continuation-in-part thereof U.S. Serial No. 08/372,783 filed January 13, 1995, and corresponding PCT Application No. PCT/US95/00656, all of which are incorporated herein by reference, disclose methods for evaluating the use of BPI as an anti-microbial agent and to enhance the effectiveness of antibiotics.

The improved therapeutic effectiveness of antibiotics may be demonstrated in *in vivo* animal models, or may be predicted on the basis of a variety of *in vitro* tests, including (1) determinations of the minimum inhibitory

concentration (MIC) of an antibiotic required to inhibit growth of a gram-negative organism for 24 hours, (2) determinations of the effect of an antibiotic on the kinetic growth curve of a gram-negative organism, and (3) checkerboard assays of the MIC of serial dilutions of antibiotic alone or in combination with serial dilutions of BPI protein product. Such improved effectiveness may be demonstrated by (a) a reduction in the number of organisms, (b) a reduced MIC, and/or (c) reversal of the organism's resistance to the antibiotic. Exemplary models or tests are described in Eliopoulos and Moellering In *Antibiotics in Laboratory Medicine*, 3rd ed. (Lorian, V., Ed.) pp. 432-492, Williams and Wilkins, Baltimore MD (1991).

"Concurrent administration," or co-treatment, as used herein includes administration of the agents, in conjunction or combination, together, or before or after each other. The BPI protein product (formulated with activity-enhancing poloxamer) and antibiotics may be administered by different routes. For example, the formulated BPI protein product may be administered intravenously while the antibiotics are administered intramuscularly, intravenously, subcutaneously, orally or intraperitoneally. Alternatively, the formulated BPI protein product may be administered intraperitoneally while the antibiotics are administered intraperitoneally or intravenously, or the formulated BPI protein product may be administered in an aerosolized or nebulized form while the antibiotics are administered, e.g., intravenously. The formulated BPI protein product and antibiotics are preferably both administered intravenously. The formulated BPI protein product and antibiotics may be given sequentially in the same intravenous line, after an intermediate flush, or may be given in different intravenous lines. The formulated BPI protein product and antibiotics may be administered simultaneously or sequentially, as long as they are given in a manner sufficient to allow both agents to achieve effective concentrations at the site of infection.

Concurrent administration of formulated BPI protein product and antibiotic is expected to provide more effective treatment of bacterial infections.

Concurrent administration of the two agents may provide greater therapeutic effects *in vivo* than either agent provides when administered singly. It may permit a reduction in the dosage of one or both agents with achievement of a similar therapeutic effect. Alternatively, the concurrent administration may produce a
5 more rapid or complete bactericidal/bacteriostatic effect than could be achieved with either agent alone.

Therapeutic effectiveness is correlated with a successful clinical outcome, and does not require that the antimicrobial agent or agents kill 100% of the organisms involved in the infection. Success depends on achieving a level of
10 antibacterial activity at the site of infection that is sufficient to inhibit the bacteria in a manner that tips the balance in favor of the host. When host defenses are maximally effective, the antibacterial effect required may be minimal. Reducing organism load by even one log (a factor of 10) may permit the host's own defenses to control the infection. In addition, augmenting an early
15 bactericidal/bacteriostatic effect can be more important than long-term bactericidal/bacteriostatic effect. These early events are a significant and critical part of therapeutic success, because they allow time for host defense mechanisms to activate. Increasing the bactericidal rate may be particularly important for infections such as meningitis, bone or joint infections [Stratton, *Antibiotics in*
20 *Laboratory Medicine*, 3rd ed. (Lorian, V., Ed.) pp. 849-879, Williams and Wilkins, Baltimore MD (1991)], or alternatively, for infections involving slow-growing organisms which may have a decreased sensitivity to antibiotics.

As used herein, "BPI protein product" includes naturally and recombinantly produced BPI protein; natural, synthetic, and recombinant
25 biologically active polypeptide fragments of BPI protein; biologically active polypeptide variants of BPI protein or fragments thereof, including hybrid fusion proteins and dimers; biologically active polypeptide analogs of BPI protein or fragments or variants thereof, including cysteine-substituted analogs; and BPI-derived peptides. The BPI protein products administered according to this
30 invention may be generated and/or isolated by any means known in the art. U.S.

004207 60296960

Patent No. 5,198,541, the disclosure of which is incorporated herein by reference, discloses recombinant genes encoding and methods for expression of BPI proteins including recombinant BPI holoprotein, referred to as rBPI₅₀ and recombinant fragments of BPI. Co-owned, copending U.S. Patent Application Ser. No.

5 07/885,501 and a continuation-in-part thereof, U.S. Patent Application Ser. No. 08/072,063 filed May 19, 1993 and corresponding PCT Application No. 93/04752 filed May 19, 1993, which are all incorporated herein by reference, disclose novel methods for the purification of recombinant BPI protein products expressed in and secreted from genetically transformed mammalian host cells in culture and
10 discloses how one may produce large quantities of recombinant BPI products suitable for incorporation into stable, homogeneous pharmaceutical preparations.

Biologically active fragments of BPI (BPI fragments) include biologically active molecules that have the same or similar amino acid sequence as a natural human BPI holoprotein, except that the fragment molecule lacks amino-
15 terminal amino acids, internal amino acids, and/or carboxy-terminal amino acids of the holoprotein. Nonlimiting examples of such fragments include a N-terminal fragment of natural human BPI of approximately 25 kD, described in Ooi et al., *J. Exp. Med.*, 174:649 (1991), and the recombinant expression product of DNA encoding N-terminal amino acids from 1 to about 193 or 199 of natural human
20 BPI, described in Gazzano-Santoro et al., *Infect. Immun.* 60:4754-4761 (1992), and referred to as rBPI₂₃. In that publication, an expression vector was used as a source of DNA encoding a recombinant expression product (rBPI₂₃) having the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in Figure 1 of Gray et al., *supra*, except that valine
25 at position 151 is specified by GTG rather than GTC and residue 185 is glutamic acid (specified by GAG) rather than lysine (specified by AAG). Recombinant holoprotein (rBPI) has also been produced having the sequence (SEQ ID NOS: 1 and 2) set out in Figure 1 of Gray et al., *supra*, with the exceptions noted for rBPI₂₃ and with the exception that residue 417 is alanine (specified by GCT) rather
30 than valine (specified by GTT). Other examples include dimeric forms of BPI

fragments, as described in co-owned and co-pending U.S. Patent Application Serial No. 08/212,132, filed March 11, 1994, and corresponding PCT Application No. PCT/US95/03125, the disclosures of which are incorporated herein by reference. Preferred dimeric products include dimeric BPI protein products wherein the monomers are amino-terminal BPI fragments having the N-terminal residues from about 1 to 175 to about 1 to 199 of BPI holoprotein. A particularly preferred dimeric product is the dimeric form of the BPI fragment having N-terminal residues 1 through 193, designated rBPI₄₂ dimer.

Biologically active variants of BPI (BPI variants) include but are not limited to recombinant hybrid fusion proteins, comprising BPI holoprotein or biologically active fragment thereof and at least a portion of at least one other polypeptide, and dimeric forms of BPI variants. Examples of such hybrid fusion proteins and dimeric forms are described by Theofan et al. in co-owned, copending U.S. Patent Application Serial No. 07/885,911, and a continuation-in-part application thereof, U.S. Patent Application Serial No. 08/064,693 filed May 19, 1993 and corresponding PCT Application No. US93/04754 filed May 19, 1993, which are all incorporated herein by reference and include hybrid fusion proteins comprising, at the amino-terminal end, a BPI protein or a biologically active fragment thereof and, at the carboxy-terminal end, at least one constant domain of an immunoglobulin heavy chain or allelic variant thereof. Similarly configured hybrid fusion proteins involving part or all Lipopolysaccharide Binding Protein (LBP) are also contemplated for use in the present invention.

Biologically active analogs of BPI (BPI analogs) include but are not limited to BPI protein products wherein one or more amino acid residues have been replaced by a different amino acid. For example, co-owned, copending U.S. Patent Application Ser. No. 08/013,801 filed February 2, 1993 and corresponding PCT Application No. US94/01235 filed February 2, 1994, the disclosures of which are incorporated herein by reference, discloses polypeptide analogs of BPI and BPI fragments wherein a cysteine residue is replaced by a different amino acid. A preferred BPI protein product described by this application is the

expression product of DNA encoding from amino acid 1 to approximately 193 or 199 of the N-terminal amino acids of BPI holoprotein, but wherein the cysteine at residue number 132 is substituted with alanine and is designated rBPI₂₁Δcys or rBPI₂₁. Other examples include dimeric forms of BPI analogs; e.g. co-owned and
5 co-pending U.S. Patent Application Serial No. 08/212,132 filed March 11, 1994, and corresponding PCT Application No. PCT/US95/03125, the disclosures of which are incorporated herein by reference.

Other BPI protein products useful according to the methods of the invention are peptides derived from or based on BPI produced by recombinant or
10 synthetic means (BPI-derived peptides), such as those described in co-owned and co-pending U.S. Patent Application Serial No. 08/504,841 filed July 20, 1995 and in co-owned and copending PCT Application No. PCT/US94/10427 filed September 15, 1994, which corresponds to U.S. Patent Application Serial No. 08/306,473 filed September 15, 1994, and PCT Application No. US94/02465 filed
15 March 11, 1994, which corresponds to U.S. Patent Application Serial No. 08/209,762, filed March 11, 1994, which is a continuation-in-part of U.S. Patent Application Serial No. 08/183,222, filed January 14, 1994, which is a continuation-in-part of U.S. Patent Application Ser. No. 08/093,202 filed July 15, 1993 (for which the corresponding international application is PCT Application
20 No. US94/02401 filed March 11, 1994), which is a continuation-in-part of U.S. Patent Application Ser. No. 08/030,644 filed March 12, 1993, the disclosures of all of which are incorporated herein by reference.

Presently preferred BPI protein products include recombinantly-produced N-terminal fragments of BPI, especially those having a molecular weight
25 of approximately between 21 to 25 kD such as rBPI₂₃ or rBPI₂₁, or dimeric forms of these N-terminal fragments (e.g., rBPI₄₂ dimer). Additionally, preferred BPI protein products include rBPI₅₀ and BPI-derived peptides.

The administration of BPI protein products is preferably accomplished with a pharmaceutical composition comprising a BPI protein product
30 and a pharmaceutically acceptable diluent, adjuvant, or carrier. The BPI protein

004207-6049660

product may be administered without or in conjunction with known surfactants, other chemotherapeutic agents or additional known anti-microbial agents. One pharmaceutical composition containing BPI protein products (e.g., rBPI₅₀, rBPI₂₃) comprises the BPI protein product at a concentration of 1 mg/ml in citrate buffered saline (5 or 20 mM citrate, 150 mM NaCl, pH 5.0) comprising 0.1% by weight of poloxamer 188 (Pluronic F-68, BASF Wyandotte, Parsippany, NJ) and 0.002% by weight of polysorbate 80 (Tween 80, ICI Americas Inc., Wilmington, DE). Another pharmaceutical composition containing BPI protein products (e.g., rBPI₂₁) comprises the BPI protein product at a concentration of 2 mg/mL in 5 mM citrate, 150 mM NaCl, 0.2% poloxamer 188 and 0.002% polysorbate 80. Such combinations are described in co-owned, co-pending PCT Application No. US94/01239 filed February 2, 1994, which corresponds to U.S. Patent Application Ser. No. 08/190,869 filed February 2, 1994 and U.S. Patent Application Ser. No. 08/012,360 filed February 2, 1993, the disclosures of all of which are incorporated herein by reference.

Other aspects and advantages of the present invention will be understood upon consideration of the following illustrative examples. Example 1 addresses the effects of poloxamer 403 or poloxamer 334 on the bactericidal activity of BPI protein products against *S. aureus* or *A. baumannii* (formerly *A. anitratus*) in water. Example 2 addresses the effects of poloxamer 333 or poloxamer 403 on the bactericidal activity of non-formulated or formulated BPI protein products against *A. baumannii*, *S. aureus*, *N. meningitidis* or *P. aeruginosa* in serum, broth or water. Example 3 addresses the effects of poloxamer 333 or poloxamer 334 on the bactericidal activity of BPI protein products against *S. pneumoniae*, *S. aureus*, *E. faecium*, or *A. baumannii* in water. Example 4 relates to uses of other poloxamers. Example 5 addresses the effects of poloxamers 188, 333, 334, 335, or 403 (with or without EDTA) on the bactericidal activity of BPI protein products against *A. baumannii*, *S. aureus*, *S. pneumoniae*, *E. faecium*, or *P. aeruginosa* in serum, Mueller-Hinton broth, tryptic soy broth, or water. Example 6 addresses the effect of compositions containing

BPI protein product and poloxamer 188, 333, 334, 335, or 403 in the presence or absence of EDTA on the susceptibility of a variety of organisms to antibiotics. Example 7 addresses the effect of compositions containing BPI protein product and an anti-bacterial activity-enhancing poloxamer surfactant in a rabbit model of corneal injury and ulceration. Example 8 addresses the effect of compositions containing BPI protein product and poloxamer 188 or 403 in the presence or absence of EDTA on the growth of various bacteria and fungi.

EXAMPLE 1

BACTERICIDAL ACTIVITY OF COMPOSITIONS CONTAINING BPI PROTEIN PRODUCT AND POLOXAMER 403 OR POLOXAMER 334 ON *S. AUREUS* AND *A. BAUMANNII* IN WATER

The bactericidal activity of therapeutic compositions comprising BPI protein product and either poloxamer 403 (PLURONIC P123, BASF Wyandotte Corp., Parsippany, NJ), heat-treated PLURONIC 123, or heat-treated poloxamer 334 (PLURONIC P104, BASF Wyandotte Corp.), was evaluated against clinical isolates of bacteria from the Microscan® library (Dade Microscan, West Sacramento, CA). Therapeutic compositions comprising 1 mg/mL rBPI₂₁ and 0.1% (w/v) PLURONIC P123, or heat-treated PLURONIC P123, were formulated by diluting a 2 mg/mL solution of "non-formulated" rBPI₂₁ (in buffer comprising 5 mM sodium citrate and 150 mM NaCl, without any surfactants) at a 1:2 ratio with a 0.2% solution of the PLURONIC P123. A therapeutic composition comprising 2 mg/mL rBPI₂₁ and 0.1% (w/v) heat-treated PLURONIC P104 was prepared. Poloxamer control solutions containing only 0.1% PLURONIC P123 or 0.1% heat-treated PLURONIC P123, and no rBPI₂₁, were also prepared.

Sterile stock solutions of 1.0% PLURONIC P123 were prepared by stirring the PLURONIC P123 in deionized water until dissolved and filtering the solution through a 0.22µm Nalgene filter unit (Nalge Co., Rochester, NY). Sterile stock solutions of heat-treated PLURONIC P123 were prepared using the following procedure: (1) making a 1.0% (w/v) solution of PLURONIC P123 in deionized water, (2) heating the solution to a boil, (3) removing it from heat, (4)

allowing it to cool to room temperature, (5) stirring until the PLURONIC P123 was completely solubilized, and (6) filtering the solution through a 0.22 μ m Nalgene filter unit for sterilization. Alternatively, the stock solutions may be autoclaved for sterilization. Heat-treated PLURONIC P104 was prepared similarly.

The bacteria to be used in the assays, *S. aureus* (Microscan® ID no. 052-106) and *A. baumannii* (Microscan® ID no. 12291), were grown on tryptic soy agar (TSA) plates (Remel, Catalog #01-920, Lenexa, KN) for 24 hours. A bacterial stock emulsion of about 4 to 7 x 10⁴ cells/mL was prepared by emulsifying bacterial colonies in sterile water for injection (Kendall McGaw Laboratory, Irvine, CA) to a 0.5 McFarland standard and diluting further by 1:10 in water. Assays were conducted by adding 944 μ L of sterile water for injection to 4.5 mL polypropylene tubes (Nalgene Cryovial, Nalge Co., Rochester, NY), followed by 40 μ L of the bacterial emulsion, followed by 16 μ L of the 1 mg/mL rBPI₂₁/0.1% PLURONIC P123 therapeutic composition or poloxamer control solution (or 8 μ L of the 2 mg/mL rBPI₂₁/0.1% PLURONIC P104 therapeutic composition). The tubes were mixed by inversion and incubated at 37°C for 30 minutes. Following incubation, the remaining colony forming units (CFU) were counted at a 10⁻² dilution by plating 10 μ L from each tube onto TSA plates, and at 10⁻⁴ dilutions by plating a 1:100 dilution of 10 μ L from each tube onto TSA plates. The TSA plates were incubated at 37°C for 18 hours and the number of bacterial colonies were visually counted. Results are shown below in Tables 1 and 2.

004207" 60295960

Table 1

	<i>S. aureus</i>	CFU
	Positive Control	150000
	16 µg/mL rBPI ₂₁ with 0.1% PLURONIC P123	26600
5	16 µg/mL rBPI ₂₁ with 0.1% heat-treated PLURONIC P123	26400
	0.1% PLURONIC P123 control	150000
	0.1% heat-treated PLURONIC P123 control	150000
	16 µg/mL rBPI ₂₁ with 0.1% heat-treated PLURONIC P104	49100

Table 2

	<i>A. baumannii</i>	CFU
	Positive Growth Control (no rBPI ₂₁ and no poloxamer)	63000
	16 µg/mL rBPI ₂₁ with 0.1% PLURONIC P123	< 100
	16 ug/mL rBPI ₂₁ with 0.1% heat-treated PLURONIC P123	100
	0.1% PLURONIC P123 control	70000
15	0.1% heat-treated PLURONIC P123 control	70000
	16 µg/mL rBPI ₂₁ with 0.1% heat-treated PLURONIC P104	100

004207" 60295950

EXAMPLE 2

BACTERICIDAL ACTIVITY OF COMPOSITIONS CONTAINING BPI PROTEIN PRODUCT AND POLOXAMER 333 ON *S. AUREUS* AND *A. BAUMANNII* IN SERUM, BROTH OR WATER

5 The bactericidal activity of therapeutic compositions comprising BPI
protein product and either poloxamer 333 (PLURONIC P103, BASF Wyandotte
Corp.) or heat-treated PLURONIC P103, was evaluated against the clinical
isolates of Example 1. Therapeutic compositions comprising 160 $\mu\text{g/mL}$ rBPI₂₁
and varying concentrations of either PLURONIC P103 or heat-treated PLURONIC
10 P103 were formulated by diluting a 2 mg/mL solution of "non-formulated" rBPI₂₁
(in buffer comprising 5 mM sodium citrate and 150 mM NaCl, without any
surfactants) with the appropriate amounts of PLURONIC P103 or heat-treated
PLURONIC P103 solutions. A "formulated" rBPI₂₁ solution containing 2 mg/mL
rBPI₂₁, 0.2% poloxamer 188 (PLURONIC F68, BASF Wyandotte Corp.), 0.002%
15 TWEEN 80 (polysorbate 80, ICI Americas, Wilmington, DE), 5 mM sodium
citrate and 150 mM NaCl was also tested for comparison. Poloxamer control
solutions containing only 0.1% PLURONIC P103 or 0.1% heat-treated
PLURONIC P103, and no rBPI₂₁, were also prepared.

 A 0.1% (w/v) solution of PLURONIC P103 was prepared by
20 stirring the PLURONIC P103 in deionized water until dissolved and filtering the
solution through a 0.22 μm cellulose acetate polystyrene filter unit (Corning Inc.,
Corning, NY). Sterile stock solutions of heat-treated PLURONIC P103 were
prepared using the following procedure: (1) making a 0.1% (w/v) solution of
PLURONIC P103 in deionized water, (2) boiling the solution for 30 minutes, (3)
25 allowing it to cool to room temperature, (4) stirring until the PLURONIC P103
was completely solubilized, and (5) filtering the solution through a 0.22 μm
Acrodisc filter unit (Gelman Sciences, Ann Arbor, MI) for sterilization.

 The bacteria to be used in the assays were grown on tryptic soy
agar (TSA) plates (Remel, Catalog #01-920, Lenexa, KN) for 24 hours. The *S.*
30 *aureus* were grown for an additional 2 hours in Fildes enriched medium. A

004201" 60295950
bacterial stock emulsion was prepared by emulsifying bacterial colonies in sterile deionized water to approximately 2.2 to 3.8×10^8 colony forming units (CFU)/mL as measured by a Microscan® Turbidity Meter (Dade Microscan, West Sacramento, CA), and diluting further by 1:10 in water. Assays were conducted
5 in 96-well flat-bottom microtiter plates (Corning, catalog# 25860-96) by adding to each well: $170 \mu\text{L}$ of serum (Sigma #S1764, St. Louis, MO), tryptic soy broth (TSB, Remel, catalog #08-942, Lenexa, KN) or sterile water for injection (Kendall McGaw); $10 \mu\text{L}$ of the bacterial emulsion (or water, as a control); $20 \mu\text{L}$ of the indicated $160 \mu\text{g/mL}$ rBPI₂₁/poloxamer therapeutic composition (or the poloxamer
10 control solution or water alone as a control). The final concentrations of bacteria in each well were about 4 to 7×10^5 CFU/mL. The well contents were mixed and the plates were incubated at 37°C for 4 hours. Following incubation, the remaining colony forming units (CFU) in each well were counted at a 10^{-2} dilution by plating $10 \mu\text{L}$ from each well onto TSA plates. The TSA plates were incubated
15 at 37°C for 24 hours and the number of bacterial colonies were visually counted. Results are shown below in Table 3; colony counts for the control wells are shown below in Tables 4 and 5.

Table 3

R o w N o.	Contents of well	100's of CFU remaining after incubation with serum and 16 µg/mL rBPI ₂₁ formulated with poloxamer at:				100's of CFU remaining after incubation with broth and 16 µg/mL rBPI ₂₁ formulated with poloxamer at:				100's of CFU remaining after incubation with water and 16 µg/mL rBPI ₂₁ formulated with poloxamer at:			
		0.1 % Formu- lation Conc.	0.05 % Formu- lation Conc.	0.01 % Formu- lation Conc.	0.005 % Formu- lation Conc.	0.1 % Formu- lation Conc.	0.05 % Formu- lation Conc.	0.01 % Formu- lation Conc.	0.005 % Formu- lation Conc.	0.1 % Formu- lation Conc.	0.05 % Formu- lation Conc.	0.01 % Formu- lation Conc.	0.005 % Formu- lation Conc.
A	(starting rBPI ₂₁ solution; type of poloxamer preparation; organism) NF rBPI ₂₁ + heat-treated P103 + <i>A. baumannii</i>	>2000	>2000	>2000	>2000	0	0	0	0	0	0	0	0
B	NF rBPI ₂₁ + P103 + <i>A. baumannii</i>	>2000	>2000	>2000	>2000	0	0	0	0	0	0	0	0
D	F rBPI ₂₁ + heat-treated P103 + <i>A. baumannii</i>	>2000	>2000	>2000	>2000	0	0	*	0	0	>2000	0	0

- 27 -

Table 3

R o w N o.	Contents of well	100's of CFU remaining after incubation with serum and 16 µg/mL rBPI ₂₁ formulated with poloxamer at:				100's of CFU remaining after incubation with broth and 16 µg/mL rBPI ₂₁ formulated with poloxamer at:				100's of CFU remaining after incubation with water and 16 µg/mL rBPI ₂₁ formulated with poloxamer at:			
		0.1 % Formu- lation Conc.	0.05 % Formu- lation Conc.	0.01 % Formu- lation Conc.	0.005 % Formu- lation Conc.	0.1 % Formu- lation Conc.	0.05 % Formu- lation Conc.	0.01 % Formu- lation Conc.	0.005 % Formu- lation Conc.	0.1 % Formu- lation Conc.	0.05 % Formu- lation Conc.	0.01 % Formu- lation Conc.	0.005 % Formu- lation Conc.
E	(starting rBPI ₂₁ solution; type of poloxamer preparation; organism)	>2000	>2000	>2000	>2000	0	0	51	252	0	0	0	0
G	F rBPI ₂₁ + P103 + <i>A. baumannii</i> NF rBPI ₂₁ + heat-treated P103 + <i>S. aureus</i>	>2000	>2000	>2000	>2000	>2000	>2000	>2000	>2000	0	0	0	0

NF = non-formulated, i.e. prepared without surfactants

F = formulated with 0.2% poloxamer 188 and 0.002% polysorbate 80

* = Contaminated

Table 4
Growth Controls for *A. baumannii* (in 100's of CFUs)

Serum	NF rBPI ₂₁ (no P103)	> 2000
	bacteria only	> 2000
	0.1% heat-treated P103 (no BPI)	> 2000*
	0.1% P103 (no BPI)	> 2000
Broth	NF rBPI ₂₁ (no P103)	> 5000
	bacteria only	> 5000
	0.1% heat-treated P103 (no BPI)	> 5000
	0.1% P103 (no BPI)	> 5000
Water	NF rBPI ₂₁	519
	bacteria only	> 2000
	0.1% heat-treated P103 (no BPI)	> 2000
	0.1% P103 (no BPI)	> 2000

*Contaminated

NF=non-formulated, i.e., prepared without surfactants

Table 5
Growth controls for *S. aureus* (in 100's of CFUs)

Serum and <i>S. aureus</i>	Serum and <i>S. aureus</i> and 0.1% heat-treated P103	Broth and <i>S. aureus</i>	Broth and <i>S. aureus</i> and 0.1% heat-treated P103	Water and <i>S. aureus</i>	Water and <i>S. aureus</i> and 0.1% heat-treated P103
2260	2540	2960	4240	550	390

Additional experiments were performed to test therapeutic compositions, prepared by diluting a variety of formulated BPI protein products with heat-treated PLURONIC P104 solution, and tested against *A. baumannii* in serial 2-fold dilutions of serum. In these experiments, it was noted that some bactericidal activity was observed at lower serum concentrations (as evidenced by a serial 50% reduction in CFUs that correlated to the serial 2-fold reduction in serum concentration). For rBPI₂₃, bactericidal activity was observed at serum concentrations of 12.5% and lower. For rBPI₂₁, bactericidal activity was observed at serum concentrations of 6.25% and lower. For rBPI₄₂ dimer and rBPI₅₀, bactericidal activity was observed at dilutions of 1.6% and lower.

In other experiments performed in a similar manner with Microscan® Pluronic Inoculum Water (Dade Microscan, West Sacramento, CA), this product exhibited bactericidal activity enhancing effect. In preliminary experiments performed in a similar manner with poloxamer 335 (PLURONIC P105, BASF Wyendotte Corp.), this poloxamer was also observed to have some bactericidal activity enhancing effect.

In further experiments, the bactericidal activity of therapeutic compositions comprising BPI protein product and a poloxamer surfactant was evaluated against clinical isolates of *Neisseria meningitidis* (Type C) (Microscan® ID No. 410-001), *Pseudomonas aeruginosa* (strain 12.4.4, provided by S.M. Opal, Brown University, Providence, Rhode Island; referenced in Ammons *et al.*, *J. Infect. Diseases*, 170:1473-82 (1994)), and *Acinetobacter baumannii* (Microscan® ID No. 12300). The following therapeutic compositions were prepared, comprising 2 mg/mL rBPI₂₁; 0.2% of either (a) poloxamer 188 (PLURONIC F68), (b) poloxamer 333 (PLURONIC P103), (c) poloxamer 334 (PLURONIC P104), (d) poloxamer 335 (PLURONIC P105) or (e) poloxamer 403 (PLURONIC P123); 0.002% polysorbate 80 (TWEEN 80); 5mM sodium citrate; and 150 mM NaCl.

Poloxamer control solutions containing only 0.2% PLURONIC P123, P103 or F68, and no rBPI₂₁, were also prepared.

5 The bacteria to be used in these additional assays were grown for approximately 24 hours on tryptic soy agar (TSA) plates (Remel, Catalog #01-920, Lenexa, KN) for *P. aeruginosa* or *A. baumannii* and chocolate agar plates (Remel Catalog # 01-301, Lenexa, KN) for *N. meningitidis*. A bacterial stock emulsion was prepared by emulsifying bacterial colonies in sterile saline (0.9% sodium chloride Irrigation water, Kendall McGaw Laboratory, Irvine, CA) to an equivalent of a 0.5 McFarland standard as measured by a
10 Microscan® Turbidity Meter (Dade Microscan, West Sacramento, CA), and diluting further by 1:10 in saline. Assays were conducted in a final volume of 1 mL by adding 982 or 974 µL of Mueller-Hinton Broth with 2% Fildes Enrichment (Remel, Catalog #06-1496, Lenexa, KN) for *N. meningitidis* or of Mueller-Hinton Broth plus Cations (CSMHB, Remel) for *P. aeruginosa* to 4.5
15 mL polypropylene tubes (Nalgene Cryovial, Nalge Co., Rochester, NY), followed by 10 µL of the bacterial emulsion (or broth media, as a control); and 8 or 16 µL of the 2 mg/mL rBPI₂₁/poloxamer therapeutic composition. The tubes were mixed by vortexing and incubated at 37°C for 8 hours. Following incubation, the remaining colony forming units (CFU) were counted at varying
20 dilutions (10⁻² to 10⁻⁷) by plating 10 µl or 100 µl of an appropriate dilution onto chocolate agar or TSA plates. The chocolate agar or TSA plates were incubated at 37°C (with 5% CO₂ for the *N. meningitidis* plates) for approximately 24 hours and the number of bacterial colonies were visually counted. Results are shown below in Tables 6 and 7.

09696709 "102400

Table 6

	<i>N. meningitidis</i> ^a	CFU
	Control	9.5x10 ⁷
	0.2% PLURONIC P123 Control ^b	7.8x10 ⁷
5	16μg/mL rBPI ₂₁ with 0.2% PLURONIC P103 ^b	3x10 ³
	32μg/mL rBPI ₂₁ with 0.2% PLURONIC P103 ^b	3x10 ³
	0.2% PLURONIC F68 Control ^b	10.1x10 ⁷
	16μg/mL rBPI ₂₁ with 0.2% PLURONIC F68 ^b	4.22x10 ⁶
	32μg/mL rBPI ₂₁ with 0.2% PLURONIC F68 ^b	1.2x10 ³

10 ^a At t = 0, there were 2.02x10⁵ organisms

^b Also contains 0.002% TWEEN 80 (polysorbate 80)

004207 " 60296960

Table 7

	<i>P. aeruginosa</i> ^a	CFU
	Media Control	6.0×10^7
	32 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC F68	1.2×10^8
5	32 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P103	$< 10^6$ ^b
	32 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P104	3×10^7
	32 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P105	$< 10^6$ ^b
	32 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P123	$< 10^6$ ^b
	<i>A. baumannii</i> ^c	CFU
10	Media Control	1.06×10^7
	16 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC F68	2.43×10^7
	16 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P103	$< 10^d$
	16 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P104	$< 10^d$
	16 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P105	$< 10^d$
15	16 $\mu\text{g/ml}$ rBPI ₂₁ with 0.2% PLURONIC P123	2.7×10^2

^a At t=0, there were 6.4×10^5 CFUs

^b No CFUs at tested dilutions of 10^{-6} and 10^{-7}

^c At t=0, there were 4.7×10^4 CFUs

^d No CFUs at tested dilutions of 10^{-1} and 10^{-2}

004201" 60296960

EXAMPLE 3

BACTERICIDAL ACTIVITY OF COMPOSITIONS CONTAINING BPI PROTEIN PRODUCT AND POLOXAMER 333 OR POLOXAMER 334 ON A VARIETY OF BACTERIA IN WATER

- 5 The bactericidal activity of therapeutic compositions comprising BPI protein product and heat-treated PLURONIC P103 or heat-treated PLURONIC P104, was evaluated against the *S. aureus* and *A. baumannii* clinical isolates of Example 1 and the additional organisms *S. pneumoniae* (Microscan® ID no. 145) and *E. faecium* (Microscan® ID no. 15773).
- 10 Therapeutic compositions comprising 500 µg/mL rBPI₂₁ in a 0.075% (w/v) concentration of either heat-treated PLURONIC P103 or heat-treated PLURONIC P104 were formulated by diluting a 2 mg/mL solution of "non-formulated" rBPI₂₁ or "formulated" rBPI₂₁ with the appropriate amounts of 0.1% heat-treated PLURONIC P103 or heat-treated PLURONIC P104
- 15 solutions. Compositions comprising 500 µg/mL non-formulated rBPI₂₁ in water alone (without any poloxamers) and poloxamer control solutions containing only 0.1% heat-treated P103 or heat-treated P104 (and no rBPI₂₁) were also prepared. A "formulated" rBPI₂₃ therapeutic composition containing 1 mg/mL rBPI₂₃, 0.1% PLURONIC F68 and 0.002% TWEEN 80 was also
- 20 tested for comparison.

- Sterile stock solutions of heat-treated PLURONIC P103 or heat-treated PLURONIC P104 were prepared using the following procedure: (1) making a 0.1% (w/v) solution of the poloxamer in deionized water, (2) heating the solution to a boil, (3) allowing it to cool to room temperature, (4) stirring
- 25 until the PLURONIC P103 was completely solubilized, and (5) filtering the solution through a 0.22µm Nalgene filter for sterilization.

- The *S. aureus*, *E. faecium* and *A. baumannii* bacteria were grown on TSA plates (Remel, Catalog #01-920, Lenexa, KN), and the *S. pneumoniae* were grown on 5% sheep blood agar plates (Remel, Catalog# 01-
- 30 200, Lenexa, KN) for 24 hours. A bacterial stock emulsion was prepared by

emulsifying bacterial colonies in sterile deionized water to approximately 2.2 to 3.8×10^8 CFU/mL as measured by a Microscan® Turbidity Meter, and diluting further by 1:10 in water. Assays for rBPI₂₁ therapeutic compositions were conducted in 96-well flat-bottom microtiter plates (Corning, catalog# 25860-96) by adding to each well: 185 μ L of TSB (Remel, catalog #08-942, Lenexa, KN) or sterile water for injection (Kendall McGaw); 8 μ L of the bacterial emulsion; 6.3 μ L of the indicated 500 μ g/mL rBPI₂₁/poloxamer therapeutic composition (or poloxamer control solution or water alone). The final concentrations of bacteria in each well were about 4 to 7×10^5 CFU/mL.

Assays for the rBPI₂₃ therapeutic composition were conducted in the same way, except 178 μ L of broth or water and 13 μ L of the 500 μ g/mL rBPI₂₃ composition were added. The well contents were mixed and the plates were incubated at 37°C. The CFUs in each well were counted at 10^{-2} and 10^{-4} dilutions after 30 minutes and 3 hours of incubation. Results at 30 minutes and 3 hours, respectively, are shown below in Tables 8 and 9.

In a preliminary experiment using therapeutic compositions containing rBPI₂₁ and heat-treated PLURONIC P104, it was noted that adding the therapeutic composition immediately after the diluent (*e.g.* water), before addition of the bacteria, provided greater enhancement of the bactericidal activity of rBPI₂₁ compared to adding the same therapeutic composition after adding bacteria. In another preliminary experiment performed using the same gram-positive and gram-negative organisms, with therapeutic compositions prepared by diluting non-formulated rBPI₂₁ with PLURONIC P103 and PLURONIC P104 solutions, no bactericidal activity was observed against the gram-positive organisms in broth at concentrations of up to 64 μ g/mL of the rBPI₂₁ therapeutic compositions.

Table 8: Incubation for 30 minutes

		NF rBPI ₂₁ alone	NF rBPI ₂₁ with 0.075% heat- treated P103	NF rBPI ₂₁ with 0.075% heat- treated P104	F rBPI ₂₁ alone	Con- trol	F rBPI ₂₃ alone	F rBPI ₂₃ with 0.075% heat- treated P103	F rBPI ₂₃ with 0.075% heat- treated P104	Con- trol
<i>S. pneumo- niae</i>	water	61	47	58	57	75	66	58	43	47
	water	0	0	1	0	1	1	1	0	0
	broth	290	305	224	355	389	337	340	350	350
	broth	4	3	0	4	4	4	5	7	1

Table 8: Incubation for 30 minutes

		NF rBPI ₂₁ alone	NF rBPI ₂₁ with 0.075 % heat- treated P103	NF rBPI ₂₁ with 0.075 % heat- treated P104	F rBPI ₂₁ alone	Con- trol	F rBPI ₂₃ alone	F rBPI ₂₃ with 0.075 % heat- treated P103	F rBPI ₂₃ with 0.075 % heat- treated P104	Con- trol
<i>S. aureus</i>	water	100 CFUs	315	227	305	TNTC	TNTC	TNTC	398	TNTC
	water	10000 CFUs	2	1	5	36	18	3	1	63
	broth	100 CFUs	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC
	broth	10000 CFUs	57	68	49	75	60	54	75	59

Table 8: Incubation for 30 minutes

		NF rBPI ₂₁ alone	NF rBPI ₂₁ with 0.075 % heat- treated P103	NF rBPI ₂₁ with 0.075 % heat- treated P104	F rBPI ₂₁ alone	Con- trol	F rBPI ₂₃ alone	F rBPI ₂₃ with 0.075 % heat- treated P103	F rBPI ₂₃ with 0.075 % heat- treated P104	Con- trol
<i>E. faecium</i>	water	100 CFUs	50	33	122	396	TNTC	180	165	TNTC
	water	10000 CFUs	1	0	3	7	15	3	4	35
	broth	100 CFUs	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC
	broth	10000 CFUs	89	28	50	55	57	51	39	38

Table 8: Incubation for 30 minutes

		NF rBPL ₂₁ alone	NF rBPL ₂₁ with 0.075 % heat- treated P103	NF rBPL ₂₁ with 0.075 % heat- treated P104	F rBPL ₂₁ alone	Con- trol	F rBPL ₂₃ alone	F rBPL ₂₃ with 0.075 % heat- treated P103	F rBPL ₂₃ with 0.075 % heat- treated P104	Con- trol
<i>A. anitrat</i>	water	100 CFUs	73	0	1	49	TNTC	203	0	TNTC
	water	10000 CFUs	0	0	0	1	16	3	0	17
	broth	100 CFUs	TNTC	68	634	TNTC	TNTC	33	67	TNTC
	broth	10000 CFUs	24	2	6	28	44	29	3	41

Table 9: Incubation for 3 hours

		NF rBPI ₂₁ alone	NF rBPI ₂₁ with 0.075 % heat- treated P103	NF rBPI ₂₁ with 0.075 % heat-treated P104	F rBPI ₂₁ alone	Control	F rBPI ₂₃ alone	F rBPI ₂₃ with 0.075 % heat- treated P103	F rBPI ₂₃ with 0.075 % heat- treated P104
<i>S. pneumoniae</i>	water	0	0	0	0	0	0	0	0
	water					0			
	broth	447	377	393	400	337	360	274	400
	broth					0			
<i>S. aureus</i>	water	12	2	5	340	TNTC	840	10	14
	water					36			
	broth	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC
	broth					144			

Table 9: Incubation for 3 hours

		NF	NF rBPI ₂₁ alone	NF rBPI ₂₁ with 0.075 % heat- treated P103	NF rBPI ₂₁ with 0.075 % heat-treated P104	F rBPI ₂₁ alone	Control	F rBPI ₂₃ alone	F rBPI ₂₃ with 0.075 % heat- treated P103	F rBPI ₂₃ with 0.075 % heat- treated P104
<i>E. faecium</i>	water	100 CFUs	1	1	3	28	TNTC	498	8	7
	water	10000 CFUs					36			
	broth	100 CFUs	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC	TNTC
	broth	10000 CFUs					167			

Table 9: Incubation for 3 hours

		NF rBPI ₂₁ alone	NF rBPI ₂₁ with 0.075 % heat- treated P103	NF rBPI ₂₁ with 0.075 % heat-treated P104	F rBPI ₂₁ alone	Control	F rBPI ₂₃ alone	F rBPI ₂₃ with 0.075 % heat- treated P103	F rBPI ₂₃ with 0.075 % heat- treated P104
<i>A. baumannii</i>	water	0	0	0	0	TNTC	0	0	0
	water					15			
	broth	58	0	0	27	TNTC	15	0	0
	broth					263			

EXAMPLE 4

BACTERICIDAL ACTIVITY OF COMPOSITIONS CONTAINING BPI PROTEIN PRODUCT AND OTHER POLOXAMER SURFACTANTS

Therapeutic compositions comprising BPI protein product and
5 other poloxamer surfactants, including poloxamer 101, poloxamer 105,
poloxamer 108, poloxamer 122, poloxamer 123, poloxamer 124, poloxamer
181, poloxamer 182, poloxamer 183, poloxamer 184, poloxamer 185,
poloxamer 188, poloxamer 212, poloxamer 215, poloxamer 217, poloxamer
231, poloxamer 234, poloxamer 235, poloxamer 237, poloxamer 238,
10 poloxamer 282, poloxamer 284, poloxamer 288, poloxamer 331, poloxamer
333, poloxamer 334, poloxamer 335, poloxamer 338, poloxamer 401,
poloxamer 402, poloxamer 403, or poloxamer 407 [see, *e.g.*, *CTFA
International Cosmetic Ingredient Dictionary*, Cosmetic, Toiletry and
Fragrance Association, Inc., Washington, DC (1991)], especially at pages 447-
15 451] are prepared and tested for capacity to enhance bactericidal activity of
BPI protein products as described above in Examples 1, 2 and 3.

EXAMPLE 5

BACTERICIDAL ACTIVITY OF COMPOSITIONS CONTAINING
BPI PROTEIN PRODUCT FORMULATED WITH POLOXAMER, WITH
20 OR WITHOUT EDTA, IN SERUM, MÜELLER-HINTON BROTH,
TRYPTIC SOY BROTH, OR WATER

The bactericidal activity of therapeutic compositions comprising
BPI protein product and PLURONIC F68, P103, P104, P105 or P123 were
evaluated against the *S. aureus* and *A. baumannii* organisms of Example 1, the
25 *S. pneumoniae* organism of Example 3, an *E. faecium* organism (Microscan®
ID No. 16866), and a strain of *P. aeruginosa* from the American Type Culture
Collection (ATCC No. 19660). Therapeutic compositions were formulated by
adding the appropriate amount of poloxamer to a stock solution of 2.2 mg/mL
rBPI₂₁ (5 mM sodium citrate, 150 mM NaCl, without poloxamer), to achieve
30 the desired 0.2% (w/v) poloxamer concentration, followed by sterile filtration.

Formulated product was stored at 2-8°C for up to 6 months. Sterile stock solutions of poloxamer were made by dissolving the poloxamer paste in water for injection (WFI, Kendall-McGaw) with mixing to a 1-5% concentration (w/v) at room temperature, followed by sterile filtration. Assays were

5 conducted in 96-well microtiter plates using WFI, tryptic soy broth (TSB, Remel, Lenexa, KN), Mueller-Hinton Broth plus Cations (CSMHB, Remel), or 40% pooled human serum in CSMHB (Sigma, St. Louis, MO) as growth media, according to the general procedure described above in Examples 2 and 3. The results (in colony forming units after 24 hours of incubation) are

10 displayed below in Table 10, and confirm that the poloxamers can enhance the bactericidal activity of BPI protein product.

007207 60295959

Table 10

Organism	Medium	Control	rBPI ₂₁ only	rBPI ₂₁ with F68	rBPI ₂₁ with P103	rBPI ₂₁ with P104	rBPI ₂₁ with P105	rBPI ₂₁ with P123
<i>A. baumannii</i>	Water TSB	2x10 ⁶	<100	<100	<100	<100	<100	<100
		3x10 ⁶	6x10 ²	3x10 ²	<100	<100	<100	<100
	CSMHB Serum	2x10 ⁶	NT	NT	<100	100	<100	300
		2x10 ⁵	2x10 ⁵	2x10 ⁵	2x10 ³	2x10 ⁵	2x10 ⁵	3x10 ³
<i>S. aureus</i>	Water TSB	8.2x10 ⁵	3.2x10 ⁴	3.6x10 ⁵	2.3x10 ⁴	3.0x10 ⁴	NT	2.7x10 ⁴
		5.4x10 ⁵	5.7x10 ⁵	7.5x10 ⁵	6.0x10 ⁵	7.2x10 ⁵	NT	NT
	CSMHB Serum	NT	NT	NT	NT	NT	NT	NT
		4.2x10 ⁵	>1x10 ⁵	>1x10 ⁵	>1x10 ⁵	NT	NT	NT
<i>S. pneumoniae</i>	Water TSB	3.2x10 ⁵	NT	>1x10 ⁵	<100	<100	400	<100
		3x10 ⁵	5x10 ⁴	4x10 ⁴	<100	5x10 ⁴	3x10 ³	<100
	CSMHB Serum	1x10 ⁷	NT	NT	2x10 ³	9x10 ²	3x10 ⁴	8x10 ³
		3x10 ⁵	NT	2.9x10 ⁵	6x10 ⁴	6x10 ⁴	6x10 ⁴	6x10 ⁴

Table 10

Organism	Medium	Control	rBPI ₂₁ only	rBPI ₂₁ with F68	rBPI ₂₁ with P103	rBPI ₂₁ with P104	rBPI ₂₁ with P105	rBPI ₂₁ with P123
<i>E. faecium</i>	Water TSB	4x10 ⁵	100	3x10 ³	100	300	300	<100
		5x10 ⁵	5x10 ⁵	5x10 ⁵	4x10 ³	3.1x10 ⁵	6x10 ⁴	1x10 ³
	CSMHB Serum	1x10 ⁷	NT	NT	8x10 ⁴	4x10 ⁵	2x10 ⁵	6x10 ⁵
		1x10 ⁸	NT	NT	5x10 ⁷	7x10 ⁷	5x10 ⁷	1x10 ⁸
<i>P. aeruginosa</i>	Water TSB	1x10 ⁷	NT	NT	3x10 ³	2x10 ³	7x10 ⁴	2x10 ³
		NT	NT	NT	NT	NT	NT	NT
	CSMHB Serum	1x10 ⁸	NT	4x10 ⁷	1x10 ⁷	5x10 ⁷	3x10 ⁷	5x10 ⁷
		4x10 ⁷	NT	3x10 ⁷	3x10 ⁶	2x10 ⁷	3x10 ⁷	2x10 ⁷

In additional experiments, the bactericidal activity of therapeutic compositions comprising BPI protein product with a poloxamer surfactant and further comprising varying concentrations of EDTA were evaluated against *P. aeruginosa* (ATCC 19660). Therapeutic compositions were formulated as described above to achieve the desired concentrations of poloxamer and rBPI₂₁ in a buffer of 5mM sodium citrate, 150 mM NaCl and 0.002% polysorbate 80. Assays were conducted generally as described in Example 2 above for *P. aeruginosa* and *A. baumannii*. Results in colony forming units after approximately 24 hours of incubation are displayed below in Table 11, and show that the addition of EDTA can further enhance the bactericidal activity of BPI protein product formulated with PLURONIC P123.

004207" 60496960

Table 11

CFU after incubation			
<i>P. aeruginosa</i> (ATCC No. 19660) ^a	2 hours incubation	4 hours incubation	6 hours incubation
Media Control (Mueller-Hinton plus cations)	4.2x10 ³	1x10 ⁵	2.1x10 ⁶
Placebo Control (Media with formulation buffer and 0.05 % EDTA)	1.3x10 ³	1.03x10 ⁵	5.4x10 ⁶
16µg/mL rBPI ₂₁ with 0.2% PLURONIC P123 without EDTA	7.0x10 ³ 8.5x10 ³	4.5x10 ⁴ 8.0x10 ⁴	5.4x10 ⁵ 3.3x10 ⁵
16µg/mL rBPI ₂₁ with 0.2% PLURONIC P123 + 0.05 % EDTA ^b	6.6x10 ³	1.34x10 ⁵	3.3x10 ⁵
128µg/mL rBPI ₂₁ with 0.2% PLURONIC P123 without EDTA	5.0x10 ³	3x10 ⁴	1x10 ⁵
128µg/mL rBPI ₂₁ with 0.2% PLURONIC P123 + 0.05 % EDTA	1.7x10 ³	3x10 ³	5x10 ²

- 20 a At t=0, there were 4.5 x 10³ organisms.
b Also contains 0.002% TWEEN 80 (polysorbate 80).

EXAMPLE 6

25 EFFECT OF COMPOSITIONS CONTAINING BPI PROTEIN PRODUCT AND POLOXAMER IN THE PRESENCE OR ABSENCE OF EDTA ON THE SUSCEPTIBILITY OF VARIOUS ORGANISMS TO ANTIBIOTICS

The effect of therapeutic compositions of rBPI₂₁ formulated with poloxamer, with or without EDTA, was evaluated on the antibiotic susceptibility of the multiple drug resistant *A. baumannii*, *S. pneumoniae*, *E. faecium* and *P. aeruginosa* organisms of Example 5. Therapeutic compositions

30

004207" 60296960
were prepared containing 2 mg/mL rBPI₂₁ (5 mM sodium citrate, 150 mM NaCl) with a 0.2% (w/v) concentration of PLURONIC F68, P103, P104, P105 or P123. The effect on the antibiotic susceptibility of the organisms was determined in Mueller-Hinton Broth plus Cations (CSMHB, Remel), or 40%
5 pooled human serum in CSMHB (Sigma, St. Louis, MO), as follows.

Isolated colonies of the organism from overnight cultures were suspended in Microscan® Inoculum Water to a concentration equivalent to a 0.5 McFarland Standard (approximately 1×10^8 CFU/ml), determined using a Microscan® turbidimeter. Aliquots were transferred to either CSMHB or 40%
10 pooled human serum in CSMHB. Each tube contained either a final concentration of 16 µg/mL rBPI₂₁ or an equivalent volume of control buffer. Minimal inhibitory concentrations (MIC) for each antibiotic tested, *i.e.* the lowest concentration of antibiotic which inhibits visible growth, were determined using gram-negative (MB and MC) and gram-positive (MA)
15 Sensititre Trays (Radiometer America, Westlake, OH), which allow for the rapid and simultaneous survey of a broad spectrum of standard antibiotics. Any other antimicrobial panel systems known in the art, such as the Microscan® (Dade Microscan, Sacramento, CA), Pasco (DIFCO, Detroit, MI) and Alamar (Alamar, Sacramento, CA) systems, may alternatively be used to
20 assay for antibiotic susceptibility.

Tables 12-15 below display a summary of the results of the antibiotic screening panels, reported for each strain tested as the MIC of the tested antibiotics in the presence of the indicated rBPI₂₁ therapeutic composition. The antibiotic susceptibility standards (interpretation of an MIC
25 as clinically resistant (R), intermediate (I) or susceptible (S) according to NCCLS standards) applicable to the organism tested appear in superscript next to the MIC. These results indicate that the improvement in therapeutic effectiveness of antibiotics that is seen with the addition of BPI protein product can be further enhanced by various poloxamer formulations.

- 49 -

Table 12

Effect of BPI protein product formulation on antibiotic susceptibility of *P. aeruginosa*

		Minimum Inhibitory Concentration (μg/mL)					
Antibiotic Tested	Medium Used	Control (no BPI)	rBPI ₂₁ with F68	rBPI ₂₁ with P103	rBPI ₂₁ with P104	rBPI ₂₁ with P105	rBPI ₂₁ with P123
Ceftizoxime	CSMHB	> 128 ^R	32 ^I	16 ^I	128 ^R	32 ^I	128 ^R
	Serum	128 ^R	> 128 ^R	16 ^I	128 ^R	16 ^I	16 ^I
Ceftriaxone	CSMHB	> 128 ^R	32 ^I	8 ^S	128 ^R	32 ^I	128 ^R
	Serum	128 ^R	> 128 ^R	16 ^I	128 ^R	16 ^I	32 ^I
Chloramphenicol	CSMHB	> 32 ^R	> 32 ^R	16 ^I	> 32 ^R	16 ^I	16 ^I
	Serum	> 32 ^R	> 32 ^R	16 ^I	16 ^I	16 ^I	16 ^I

- 50 -

Table 13

Effect of BPI protein product formulation on antibiotic susceptibility of *A. baumannii*

		Minimum Inhibitory Concentration (μg/mL)						
Antibiotic Tested	Medium Used	Control (no BPI)	rBPI ₂₁ with F68	rBPI ₂₁ with P103	rBPI ₂₁ with P104	rBPI ₂₁ with P105	rBPI ₂₁ with P123	
Ceftazidime	CSMHB	16 ^I	32 ^R	<4 ^S	<4 ^S	<4 ^S	<4 ^S	
	Serum	>32 ^R	32 ^R	16 ^I	16 ^I	16 ^I	16 ^I	
Ceftriaxone	CSMHB	128 ^R	>128 ^R	<1 ^S	<1 ^S	<1 ^S	4 ^S	
	Serum	>128 ^R	>128 ^R	>128 ^R	>128 ^R	>128 ^R	>128 ^R	
Chloramphenicol	CSMHB	>4 ^R	1 ^S	<0.5 ^S	1 ^S	<0.5 ^S	<0.5 ^S	
	Serum	>4 ^R	>4 ^R	2 ^S	4 ^R	>4 ^R	>4 ^R	

Table 14

Effect of BPI protein product formulation on antibiotic susceptibility of *S. pneumoniae*

Antibiotic Tested	Medium Used	Minimum Inhibitory Concentration ($\mu\text{g/mL}$)					
		Control (no BPI)	rBPI ₂₁ with F68	rBPI ₂₁ with P103	rBPI ₂₁ with P104	rBPI ₂₁ with P105	rBPI ₂₁ with P123
Oxacillin	CSMHB	32 ^R	32 ^R	<0.25 ^S	0.5 ^S	1 ^S	0.5 ^S
	Serum	32 ^R	> 32 ^R	32 ^R	32 ^R	32 ^R	32 ^R

- 52 -

Table 15

Effect of BPI protein product formulation on antibiotic susceptibility of *E. faecium*

		Minimum Inhibitory Concentration (μg/mL)						
Antibiotic Tested	Medium Used	Control (no BPI)	rBPI ₂₁ with F68	rBPI ₂₁ with P103	rBPI ₂₁ with P104	rBPI ₂₁ with P105	rBPI ₂₁ with P123	
Rifampicin	CSMHB	4 ^R	0.5 ^S	0.5 ^S	0.5 ^S	0.5 ^S	0.5 ^S	
	Serum	4 ^R	1 ^S	1 ^S	>4 ^R	0.5 ^S	0.5 ^S	
Chloramphenicol	CSMHB	16 ^I	<4 ^S	<4 ^S	<4 ^S	<4 ^S	<4 ^S	
	Serum	8 ^S	8 ^S	8 ^S	8 ^S	8 ^S	8 ^S	
Ciprofloxacin	CSMHB	2 ^I	1 ^S	<0.5 ^S	1 ^S	1 ^S	1 ^S	
	Serum	2 ^I	1 ^S	2 ^I	2 ^I	2 ^I	2 ^I	

In additional experiments, a BPI protein product, rBPI₂₁, was formulated with an anti-bacterial activity enhancing poloxamer, specifically PLURONIC P123, and with various concentrations of EDTA, and was evaluated for its effect on the antibiotic susceptibility of a *Pseudomonas*
5 *aeruginosa* (ATCC 19660). Antibiotic susceptibility was determined using Microscan® panel plates (Dade Microscan, West Sacramento, CA) that allow simultaneous determination of minimum inhibitory concentrations for a number of different antibiotics.

The antimicrobial susceptibility tests performed on the
10 Microscan® panel plates are miniaturizations of the broth dilution susceptibility test. Antimicrobial agents are serially diluted in Mueller-Hinton broth (supplemented with calcium and magnesium, or with sodium chloride for oxacillin, or with thymidine phosphorylase for trimethoprim, sulfamethoxazole and trimethoprim/ sulfamethoxazole) to concentrations bridging the range of
15 clinical interest. One well on the 96-well Microscan® plate is a growth control well that contains dehydrated broth only. The remaining wells contain dehydrated broth and antibiotic (or broth and biochemical reagent indicator), which is rehydrated to the desired concentration by inoculation of a standardized suspension of test organism. The chromogenic biochemical agent
20 indicators are used to identify and characterize the species of bacteria based on detection of pH changes and substrate utilization. After incubation overnight, the minimum inhibitory concentration (MIC) of an antibiotic for the test organism is determined by observing the well with the lowest concentration of the antibiotic that shows inhibition of growth. Gram-negative and gram
25 positive organisms may be tested using any of the Microscan® panel plates (Microscan®, Dade Microscan, West Sacramento, CA). In these experiments with *P. aeruginosa*, the MIC Plus Type 2 panel plates were used. The concentrations of antibiotics tested in this panel plate are shown below in Table 16. The antibiotic susceptibility standards (interpretation of an MIC as
30 resistant, intermediate or susceptible according to Microscan®'s NCCLS-

09696709-102400

derived standards) applicable to the gram-negative organisms that may be tested in each panel plate appear below in Table 16A.

09696709 102400

Table 16
ANTIBIOTIC CONCENTRATIONS TESTED IN
MIC PLUS TYPE 2 PANEL PLATE

	Antibiotic	Two-Fold Serial Dilutions Tested (µg/ml)
5	Amoxicillin/K Clavulanate	1/0.5-32/16
	Ampicillin/Sulbactam	1/0.5-32/16
	Azlocillin	64
	Aztreonam	1-32
	Carbenicillin	16-128
10	Cefamandole	4-32
	Cefonicid	2-16
	Cefoperazone	4-32
	Cefotaxime	2-64
	Cefotetan	4-32
15	Ceftazidime	1-32
	Ceftizoxime	2-32
	Ceftriaxone	2-64
	Chloramphenicol	2-16
	Ciprofloxacin	0.25-4
20	Imipenem	0.5-16
	Mezlocillin	16-128
	Netilmicin	2-16
	Ticarcillin	16-128
	Ticarcillin/K Clavulanate	16-128

00420T" 60/96960

Table 16A
MICROSCAN MIC PLUS TYPE 2 ANTIBIOTIC
SUSCEPTIBILITY RANGES FOR GRAM-NEGATIVE BACTERIA

	Antibiotic	MIC (µg/ml)		
		Resistant	Intermediate	Susceptible
5	Amoxicillin/K Clavulanate	≥ 32/16	16/8	≤ 8/4
	Ampicillin/Sulbactam	≥ 32/16	16/8	≤ 8/4
	Azlocillin ^P	> 64		≤ 64
	Aztreonam	≥ 32	16	≤ 8
10	Carbenicillin ^E	≥ 64	32	≤ 16
	Carbenicillin ^P	> 128		≤ 128
	Cefamandole	≥ 32	16	≤ 8
	Cefonicid	> 16	16	≤ 8
	Cefoperazone	> 32	32	≤ 16
	Cefotaxime	≥ 64	16-32	≤ 8
15	Cefotetan	> 32	32	≤ 16
	Ceftazidime	≥ 32	16	≤ 8
	Ceftizoxime	> 32	16-32	≤ 8
	Ceftriaxone	≥ 64	16-32	≤ 8
	Chloramphenicol	> 16	16	≤ 8
	Ciprofloxacin	≥ 4	2	≤ 1
20	Imipenem	≥ 16	8	≤ 4
	Mezlocillin ^E	≥ 128	32-64	≤ 16
	Mezlocillin ^P	≥ 128		≤ 64
	Netilmicin	> 16	16	≤ 8
25	Ticarcillin ^E	≥ 128	32-64	≤ 16
	Ticarcillin ^P	≥ 128		≤ 64
	Ticarcillin/K Clavulanate ^E	≥ 128	32-64	≤ 16

0996709 102400

Table 16A
MICROSCAN MIC PLUS TYPE 2 ANTIBIOTIC
SUSCEPTIBILITY RANGES FOR GRAM-NEGATIVE BACTERIA

Antibiotic	MIC ($\mu\text{g/ml}$)		
	Resistant	Intermediate	Susceptible
Ticarcillin/K Clavulanate ^P	≥ 128		≤ 64

^E *Enterobacteriaceae* only

^P *Pseudomonas* only

- For these experiments with *P. aeruginosa*, the following
- 5 procedure was performed: The organism was streaked onto TSA plates (Remel, Lenexa, KN) and incubated for 18-24 hours overnight. Well-isolated colonies from the plates were emulsified in 3 ml of sterile Inoculum Water (catalog no. B1015-2, MicroScan® system, Dade Microscan, West Sacramento, CA) to a final turbidity equivalent to 0.5 McFarland Barium Sulfate standard.
 - 10 This cell suspension was vortexed for 2 to 3 seconds and 100 μl was transferred to glass tubes containing 25 ml of Inoculum Water with Pluronic-D (catalog no. B1015-7, MicroScan® system, Dade Microscan, West Sacramento, CA) (hereinafter "Pluronic Inoculum Water"), or 25 ml of Pluronic Inoculum Water into which rBPI₂₁ in 0.2% PLURONIC P123, 0.002% TWEEN 80,
 - 15 5mM sodium citrate, 150 mM NaCl ("rBPI₂₁/P123") had been diluted to 64 $\mu\text{g/ml}$ rBPI₂₁.

- The 25 ml of this inoculum containing rBPI₂₁ was mixed by inversion and poured into a tray. The inoculum was drawn up into a manual
- 96-well pipetting system (RENOK™ rehydrator-inoculator system, Dade
 - 20 Microscan, West Sacramento, CA) designed for use with the Microscan® panel plates, and 110 μl of the inoculum was delivered to each well of a Microscan® MIC Plus Type 2 panel plate. When added to the wells, this inoculum achieves a final bacterial concentration of 4×10^5 to 7×10^5 CFU/ml. The

panel plates were then incubated at 35°C for 15-24 hours and read visually for cell growth.

No growth was defined as a slight whiteness in the well or a clear broth. Growth appeared as turbidity which could take the form of a white haze throughout the well, a white button in the center of the well, or a fine granule growth throughout the well. All wells were read against a black indirectly lighted background. Visual results of the biochemical reactions were read into a database for bacterial identification. The MICs for each antibiotic tested were determined by identifying the lowest concentration of antibiotic which inhibited visible growth.

Table 17 below displays a summary of the results of the antibiotic screening panel. The antibiotic susceptibility standards, which are the interpretation of an MIC as resistant, intermediate or susceptible according to Microscan®'s NCCLS-derived standards, are indicated in Table 16 as superscripts R, I and S, respectively. These data show that EDTA further enhanced the anti-bacterial activity of the rBPI₂₁/P123 formulation by reversing resistance of the tested *P. aeruginosa* strain to cefonicid, cefotetan, cefamandole, chloramphenicol, ampicillin/sulbactam, and amoxicillin/k clavulanate, and by increasing the susceptibility of the tested *P. aeruginosa* strain to ceftizoxime, cefotaxime, ceftriaxone, and aztreonam.

09696709-102400

<p>TABLE 17 Effects Of rBPI₂₁/P123 Formulation ± Antibiotics On <i>P. aeruginosa</i> (ATCC 19660) with varying concentrations of EDTA</p>						
Antibiotic Tested	Minimum Inhibitory Concentration of Antibiotic (µg/mL)					
	Control (No BPI ₂₁)	With 0% EDTA	With 0.01% EDTA	With 0.05% EDTA	With 0.1% EDTA	
Ceftizoxime	32 ^I	16 ^I	<2 ^S	8 ^S	<2 ^S	
Ceftazidime	2 ^S	<1 ^S	<1 ^S	<1 ^S	<1 ^S	
Cefotaxime	32 ^I	16 ^I	4 ^S	<2 ^S	<2 ^S	
Ceftriaxone	16 ^I	4 ^S	8 ^S	<2 ^S	<2 ^S	
Cefoperazone	<4 ^S	<4 ^S	<4 ^S	<4 ^S	<4 ^S	
Cefonicid	>16 ^R	>16 ^R	<2 ^S	<2 ^S	<2 ^S	
Cefotetan	>32 ^R	>32 ^R	<4 ^S	<4 ^S	<4 ^S	
Netilmicin	4 ^S	<2 ^S	<2 ^S	<2 ^S	<2 ^S	
Cefamandole	>32 ^R	>32 ^R	>32 ^R	>32 ^R	<4 ^S	

<p>TABLE 17 Effects Of rBPI₂₁/P123 Formulation ± Antibiotics On <i>P. aeruginosa</i> (ATCC 19660) with varying concentrations of EDTA</p>					
Antibiotic Tested	Minimum Inhibitory Concentration of Antibiotic (µg/mL)				
	Control (No BPI ₂₁)	With 0% EDTA	With 0.01% EDTA	With 0.05% EDTA	With 0.1% EDTA
Chloramphenicol	> 16 ^R	8 ^S	16 ^I	< 2 ^S	< 2 ^S
Ticarcillin	< 16 ^S	< 16 ^S	< 16 ^S	< 16 ^S	< 16 ^S
Azlocillin	< 64 ^S	< 64 ^S	< 64 ^S	< 64 ^S	< 64 ^S
Imipenem	1 ^S	1 ^S	< 0.5 ^S	< 0.5 ^S	< 0.5 ^S
Amp/Sulbact	> 32 ^R	> 32 ^R	< 1 ^S	16 ^I	16 ^I
Aztreonam	4 ^S	4 ^S	< 1 ^S	2 ^S	< 1 ^S
Amox/K Clavulanate	> 32 ^R	> 32 ^R	< 1 ^S	32 ^R	< 1 ^S
Ciprofloxacin	< 0.25 ^S	< 0.25 ^S	< 0.25 ^S	< 0.25 ^S	< 0.25 ^S

TABLE 17 Effects Of rBPI₂₁/P123 Formulation ± Antibiotics On <i>P. aeruginosa</i> (ATCC 19660) with varying concentrations of EDTA					
Antibiotic Tested	Minimum Inhibitory Concentration of Antibiotic (µg/mL)				
	Control (No BPI ₂₁)	With 0% EDTA	With 0.01% EDTA	With 0.05% EDTA	With 0.1% EDTA
Ticar/K Clavulanate	< 16 ^s	< 16 ^s	< 16 ^s	< 16 ^s	< 16 ^s
Mezlocillin	< 16 ^s	< 16 ^s	< 16 ^s	< 16 ^s	< 16 ^s
Carbenicillin	32 ⁱ	< 16 ^s	< 16 ^s	< 16 ^s	< 16 ^s

EXAMPLE 7

**ANTI-BACTERIAL ACTIVITY OF COMPOSITIONS CONTAINING
BPI PROTEIN PRODUCT AND POLOXAMER 188 OR POLOXAMER 403
ON *PSEUDOMONAS* INFECTION
IN A RABBIT CORNEAL ULCERATION MODEL**

The anti-bacterial activity of therapeutic compositions comprising BPI protein products with a poloxamer surfactant was evaluated in the context of administration both prior to and after *Pseudomonas* infection in a corneal infection/ulceration rabbit model.

For these experiments, the infectious organism was a strain of *Pseudomonas aeruginosa* 19660 obtained from the American Type Culture Collection (ATCC, Rockville, MD). The freeze dried organism was resuspended in nutrient broth (Difco, Detroit, MI) and grown at 37°C with shaking for 18 hours. The culture was centrifuged following the incubation in order to harvest and wash the pellet. The washed organism was Gram stained in order to confirm purity of the culture. A second generation was cultured using the same techniques as described above. Second generation cell suspensions were diluted in nutrient broth and adjusted to an absorbance of 1.524 at 600 nm, a concentration of approximately 6.55×10^9 CFU/ml. A final 1.3×10^6 fold dilution in nutrient broth yielded 5000 CFU/mL or 1.0×10^2 CFU/0.02 mL. Plate counts for CFU determinations were made by applying 100 µL of the diluted cell suspension to nutrient agar plates and incubating them for 24-48 hours at 37°C.

The animals used were New Zealand White rabbits, maintained in rigid accordance to both SERI guidelines and the ARVO Resolution on the Use of Animals in Research. A baseline examination of all eyes was conducted prior to injection in order to determine ocular health. All eyes presented with mild diffuse fluorescein staining, characteristically seen in the normal rabbit eye. The health of all eyes fell within normal limits. Rabbits weighing between 2.5 and 3.0 kg were anesthetized by intramuscular injection of 0.5-0.7 mL/kg rodent cocktail (100 mg/mL ketamine, 20 mg/mL xylazine, and 10

mg/mL acepromazine). One drop of proparacaine hydrochloride (0.5% Ophthaine, Bristol-Myers Squibb) was applied to the eye prior to injection. Twenty microliters of bacterial suspension (1×10^2 CFU) prepared as described above was injected into the central corneal stroma of a randomly assigned eye while the other eye remained naive. Injections, simulating perforation of the corneal epithelium, were performed using a 30-gauge 1/2-inch needle and a 100 μ L syringe.

For the first series of experiments, a 5-day dosing regimen of BPI protein product (test drug) was as follows: on Day 0 of the study, 40 μ L of test drug or vehicle control was delivered to the test eye at 2 hours (-2) and 1 hour (-1) prior to intrastromal bacterial injection (time 0), then at each of the following 10 hours (0 through +9 hrs) post-injection for a total of 12 doses (40 μ L/dose); on each of Days 1-4 of the study, 40 μ L of test drug or vehicle control was delivered to the test eye at each of 10 hours (given at the same time each day, e.g., 8am-5pm). For these experiments, to test the poloxamer 188-containing therapeutic composition, 5 animals were treated with rBPI₂₁ (2 mg/mL in 5 mM citrate, 150 mM NaCl, 0.2% poloxamer 188, 0.002% polysorbate 80) and 5 with buffered vehicle, and to test the poloxamer 103-containing therapeutic composition, 5 animals were treated with rBPI₂₁ (2 mg/mL in 5 mM citrate, 150 mM NaCl, 0.2% poloxamer 403, 0.002% polysorbate 80) and 5 animals with placebo (5 mM citrate, 150 mM NaCl, 0.2% poloxamer 403, 0.002% polysorbate 80).

Eye examinations were conducted two times each day for each 5-day study via slit lamp biomicroscopy to note clinical manifestations. Conjunctival hyperemia, chemosis and tearing, mucous discharge were graded. The grading scale for hyperemia was: 0 (none); 1 (mild); 2 (moderate); and 3 (severe). The scale for grading chemosis was: 0 (none); 1 (visible in slit lamp); 2 (moderate separation); and 3 (severe ballooning). The scale for grading mucous discharge was: 0 (none) 1 slight accumulation); 2 (thickened discharge); and 3 (discrete strands). Photophobia was recorded as present or

absent. Tearing was recorded as present or absent. The corneal ulcer, when present, was assessed with respect to height (mm), width (mm), and depth (% of corneal thickness). Neovascularization was graphed with respect to the affected corneal meridians. Photodocumentation was performed daily as symptoms progressed throughout the experimental procedure.

At the completion of the 5-day study period, all rabbits were sacrificed via a lethal dose of sodium pentobarbital (6 grs/mL). Corneas were harvested and fixed in half-strength Karnovsky's fixative. The corneas were processed for light microscopy using Gram stain to assay for the presence of microbial organisms and using hematoxylin and eosin to assay for cellular infiltrate.

Examinations were conducted at 4, 24, 28, 48, 52, 72, 76, and 96 hours after injection of *Pseudomonas*. The results of these examinations are reported in Table 18 for the therapeutic composition comprising rBPI₂₁ with poloxamer 403, which provided the most potent effects.

09696709.102400

Table 18

Summary of Clinical Observations for therapeutic composition containing rBPI ₂₁ and poloxamer 403										
	Hyperemia*		Chemosis*		Mucous*		Neovas- cularization		Ulcer Size (mm)	
Examination	rBPI ₂₁	Plbo.	rBPI ₂₁	Plbo.	rBPI ₂₁	Plbo.	rBPI ₂₁	Plbo.	rBPI ₂₁	Plbo.
Exam 1 4 hours	1.2	1.0	0.2	0.3	0.5	0	None	None	1 ulcer 2mm	1.4
Exam 2 24 hours	0.9	1.6	0.2	1.0	0.3	0.5	None	None	1 ulcer 6mm	3.4
Exam 3 28 hours	0.6	1.7	0.2	1.1	0.6	1.3	None	None	1 ulcer 7mm	5.2
Exam 4 48 hours	0.6	2.4	0.2	1.3	0.4	2.1	None	None	1 ulcer 12mm 1 melt	11.4 3 melt 1 thinning
Exam 5 52 hours	0.8	2.4	0.2	1.2	0.2	1.6	None	Yes (1/5)	1 ulcer 12mm 1 melt	11.4 3 melt 1 thinning
Exam 6 72 hours	0.6	2.4	0	0.8	0.2	1.0	None	Yes (1/5)	1 ulcer 12mm melt & thin	11.4 4 melt 1 thinning
Exam 7 76 hours	0.6	2.4	0	0.2	0.2	0.8	None	Yes (2/5)	1 ulcer 12mm melt & thin	11.4 4 melt 3 thinning
Exam 8 96 hours	0.6	2.4	0	0.2	0.2	0.8	None	Yes (2/5)	1 ulcer 12mm melt & thin	11.4 4 melt 3 thinning

* Mean scores of clinical observations graded on a scale of 0 (none) to 3 (severe).

004201" 60295950

The results set out in Table 18 reveal that treatment of the eye prior to and after perforation injury and injection of *Pseudomonas* provided substantial benefits in terms of reduced hyperemia, chemosis and mucous formation, as well as reduction in incidence of neovascularization along with reduced incidence and severity of corneal ulceration. At four hours after *Pseudomonas* injection, fluorescein staining of the cornea in both treated and control animals revealed small areas of staining consistent with the injection (puncture) injury. At 28 hours after injection, the rBPI₂₁/poloxamer 403 treated eye evidenced clear ocular surfaces and typically were free of evidence of hyperemia, chemosis and mucous discharge while the vehicle treated eyes showed clouding of the ocular surface resulting from corneal edema and infiltration of white cells. Iritis was conspicuous in the vehicle treated eyes at 28 hours after injection and fluorescein dye application typically revealed areas of devitalized epithelium; severe hyperemia and moderate to severe chemosis and mucous discharge were additionally noted. At 48 hours after injection, mild hyperemia was sometimes noted in the rBPI₂₁/poloxamer 403 treated eyes but mucous discharge and chemosis were absent; the rBPI₂₁/poloxamer 403 treated corneas were otherwise typically clear and healthy appearing, as evidenced by the application of fluorescein dye. Vehicle treated eyes at 48 hours post infection displayed severe hyperemia, chemosis and mucous discharge were present; some corneas displayed corneal melting and thinning along with an ulcerating area clouded as a result of edema, cellular infiltration and fibrin deposition. At 52 hours following injection, rBPI₂₁/poloxamer 403 treated eyes exhibited clear and healthy corneas which resisted staining with fluorescein, indicating that the formulation is safe and non-toxic to the corneal epithelium. In vehicle treated eyes at 52 hours post infection, sloughing of corneal epithelium was evident and while chemosis was decreasing, hyperemia was severe. In these experiments, several vehicle treated eyes presented with neovascularization, with vessels

09696709 "102400

growing inward toward the central cornea. This manifestation was not noted in any rBPI₂₁/poloxamer 403 treated eye.

Pathohistological evaluation of the rBPI₂₁/poloxamer 403 treated corneas stained with hematoxylin and eosin revealed healthy, intact corneal epithelium and stroma; the tissue was free of white cell infiltration. In contrast, evaluation of the vehicle treated corneas revealed absence of an epithelium and extensive infiltration of white cells into the corneal stroma.

Additional pathohistological evaluation of the rBPI₂₁/poloxamer 403 treated corneas stained with toluidine blue also revealed healthy, intact corneal epithelium and stroma, and further revealed corneal tissue free of *Pseudomonas* organisms. In contrast, evaluation of the vehicle treated corneas revealed rod shaped *Pseudomonas* organisms in the tissue and the presence of white cells advancing toward the organisms in the tissue. These results indicate effective corneal penetration of the rBPI₂₁/poloxamer 403 and effective sterilization of the tissue without neovascularization.

The rBPI₂₁/poloxamer 403 therapeutic composition tested in these experiments achieved the most dramatic beneficial antimicrobial and anti-angiogenic effects when compared with those of the rBPI₂₁/poloxamer 188 therapeutic composition tested in this severe *Pseudomonas* injury/infection rabbit model. Benefits in terms of suppression of neovascularization were noted for treatment with the rBPI₂₁/poloxamer 188 composition and no significant effects in reduction of hyperemia, chemosis, mucous formation and tearing were noted. The contrast in efficacy of the BPI₂₁/poloxamer 403 composition with the lesser efficacy of the rBPI₂₁/poloxamer 188 composition in these experiments suggested that formulation components, dosage and dosage regimen may all have a significant role in optimizing beneficial effects associated with methods according to the invention.

EXAMPLE 8

BACTERIAL AND FUNGAL GROWTH-INHIBITORY ACTIVITY OF COMPOSITIONS CONTAINING BPI PROTEIN PRODUCT AND POLOXAMER 188 OR POLOXAMER 403 IN THE PRESENCE OR ABSENCE OF EDTA

5

The antimicrobial preservative effectiveness of therapeutic compositions comprising BPI protein product and poloxamer surfactant were evaluated according to the U.S. Pharmacopeia (USP) microbiological test protocol (USP 23, [51] Antimicrobial Preservatives-Effectiveness, p. 1681) against the standard bacterial and fungal test microorganisms: *Escherichia coli* (ATCC No. 8739), *Pseudomonas aeruginosa* (ATCC No. 9027), *Staphylococcus aureus* (ATCC No. 6538), *Candida albicans* (ATCC No. 10231) and *Aspergillus niger* (ATCC No. 16404).

10

For these experiments, a small volume of the cultures from each of the five test microorganisms prepared according to the USP protocol was added into sterile containers with a solution of 2 mg/ml rBPI₂₁, 0.2% poloxamer 188 (PLURONIC F68) or poloxamer 403 (PLURONIC P123), 0.002% TWEEN 80, 5mM sodium citrate and 150 mM sodium chloride. In some experiments, these solutions additionally contained various concentrations of EDTA. Aliquots of test solution were removed from the containers at various time periods after inoculation with the microorganisms (i.e., 7, 14, 21, and 28 days) and plated to determine the number of colony forming units (CFU) of each of the five microorganisms. According to USP standards, the product shows effectiveness if (a) the concentrations of viable bacteria are reduced to not more than 0.1% of the initial concentrations by the fourteenth day; (b) the concentrations of viable fungi remain at or below the initial concentrations during the first 14 days; and (c) the concentration of each test microorganism remains at or below these designated levels during the remainder of the 28-day test period.

15

20

25

30

The results of initial testing of rBPI₂₁/poloxamer 188 and rBPI₂₁/poloxamer 403 compositions are shown in Tables 19A-19B below.

Table 19A

CFUs after incubation with 2 mg/mL rBPI ₂₁ /0.2% poloxamer 188					
Organisms	Initial	7 Day	14 Day	21 Day	28 Day
<i>E. coli</i>	4.9 x 10 ⁶	1.67 x 10 ³	6.7 x 10 ²	< 1	< 1
<i>P. aeruginosa</i>	1.46 x 10 ⁶	1.7 x 10 ²	5.8 x 10 ³	4.7 x 10 ⁴	2.05 x 10 ⁵
<i>S. aureus</i>	3.6 x 10 ⁶	7.5 x 10 ²	7.8 x 10 ¹	2.9 x 10 ²	1.15 x 10 ³
<i>C. albicans</i>	3.3 x 10 ⁶	2.62 x 10 ⁶	2.62 x 10 ⁶	2.96 x 10 ⁶	4.1 x 10 ⁶
<i>A. niger</i>	5.5 x 10 ⁵	8.5 x 10 ⁵	6.9 x 10 ⁵	2.6 x 10 ⁵	7.1 x 10 ⁵

Table 19B

CFUs after incubation with 2 mg/mL rBPI ₂₁ /0.2% poloxamer 403					
Organisms	Initial	7 Day	14 Day	21 Day	28 Day
<i>E. coli</i>	7.2 x 10 ⁵	0	0	0	0
<i>P. aeruginosa</i>	1.02 x 10 ⁵	0	0	0	0
<i>S. aureus</i>	6.2 x 10 ⁵	1.8 x 10 ¹	0	0	0
<i>C. albicans</i>	3.4 x 10 ⁵	1 x 10 ⁵	7.4 x 10 ⁴	7.9 x 10 ⁴	7.9 x 10 ⁴
<i>A. niger</i>	1.9 x 10 ⁵	1.5 x 10 ⁵	1.4 x 10 ⁵	1.4 x 10 ⁵	8.9 x 10 ⁴

When additional compositions of rBPI₂₁/poloxamer 403 as described above were prepared with concentrations of 0.01%, 0.05% and 0.1% EDTA and tested in the experiments shown in Table 19B above, the results obtained were comparable to those shown in Table 19B above for all organisms.

In additional experiments, other compositions of 2mg/mL rBPI₂₁, 0.2% PLURONIC P123, 0.002% TWEEN 80, 5mM sodium citrate, 150 mM sodium chloride with and without 0.05% EDTA were evaluated for effectiveness as described above. The results are shown in Table 20 below. In these experiments, 0.05% EDTA further enhanced the antimicrobial effectiveness of the rBPI₂₁/poloxamer 403 composition.

TABLE 20

CFUs after incubation with 2 mg/mL rBPL ₂₇ /0.2% poloxamer 403 ± 0.05% EDTA					
Organisms	Initial	7 Day -EDTA/+ EDTA	14 Day -EDTA/+ EDTA	21 Day -EDTA/+ EDTA	28 Day -EDTA/+ EDTA
<i>E. coli</i>	1.97 x 10 ⁵	10	1	1	1
<i>P. aeruginosa</i>	7 x 10 ⁴	1	1	1	1
<i>S. aureus</i>	9.4 x 10 ⁴	1	3.9 x 10 ³	1	1
<i>C. albicans</i>	3 x 10 ³	8.8 x 10 ³	1.5 x 10 ³	3 x 10 ²	5 x 10 ⁵
<i>A. niger</i>	7.25 x 10	1.8 x 10 ⁴	1.2 x 10 ⁴	4.1 x 10 ⁴	1.4 x 10 ⁴
			1.45 x 10 ⁴	3.4 x 10 ²	1.7 x 10 ²
			4.1 x 10 ⁴	4.4 x 10 ⁴	1.66 x 10 ⁴

Numerous modifications and variations of the above-described invention are expected to occur to those of skill in the art. Accordingly, only such limitations as appear in the appended claims should be placed thereon.

09696709 102400

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Lambert, Lewis H., Jr.
- (ii) TITLE OF INVENTION: Improved Therapeutic Compositions Comprising Bactericidal/Permeability-Increasing (BPI) Protein Products
- (iii) NUMBER OF SEQUENCES: 2
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
 - (B) STREET: 6300 Sears Tower, 233 South Wacker Drive
 - (C) CITY: Chicago
 - (D) STATE: Illinois
 - (E) COUNTRY: United States of America
 - (F) ZIP: 60606-6402
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/372,104
 - (B) FILING DATE: 13-JAN-1995
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Sharp, Jeffrey S.
 - (B) REGISTRATION NUMBER: 31,879
 - (C) REFERENCE/DOCKET NUMBER: 27129/33071
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 312/474-6300
 - (B) TELEFAX: 312/474-0448
 - (C) TELEX: 25-3856

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1813 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 31..1491
- (ix) FEATURE:

004207 60295950

(A) NAME/KEY: mat_peptide
(B) LOCATION: 124..1491

(ix) FEATURE:
(A) NAME/KEY: misc_feature
(D) OTHER INFORMATION: "rBPI"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAGGCCTTGA GGTTTTGGCA GCTCTGGAGG	ATG AGA GAG AAC ATG GCC AGG GGC	54
	Met Arg Glu Asn Met Ala Arg Gly	
	-31 -30 -25	
CCT TGC AAC GCG CCG AGA TGG GTG TCC CTG ATG GTG CTC GTC GCC ATA	102	
Pro Cys Asn Ala Pro Arg Trp Val Ser Leu Met Val Leu Val Ala Ile		
	-20 -15 -10	
GGC ACC GCC GTG ACA GCG GCC GTC AAC CCT GGC GTC GTG GTC AGG ATC	150	
Gly Thr Ala Val Thr Ala Ala Val Asn Pro Gly Val Val Val Arg Ile		
	-5 1 5	
TCC CAG AAG GGC CTG GAC TAC GCC AGC CAG CAG GGG ACG GCC GCT CTG	198	
Ser Gln Lys Gly Leu Asp Tyr Ala Ser Gln Gln Gly Thr Ala Ala Leu		
	10 15 20 25	
CAG AAG GAG CTG AAG AGG ATC AAG ATT CCT GAC TAC TCA GAC AGC TTT	246	
Gln Lys Glu Leu Lys Arg Ile Lys Ile Pro Asp Tyr Ser Asp Ser Phe		
	30 35 40	
AAG ATC AAG CAT CTT GGG AAG GGG CAT TAT AGC TTC TAC AGC ATG GAC	294	
Lys Ile Lys His Leu Gly Lys Gly His Tyr Ser Phe Tyr Ser Met Asp		
	45 50 55	
ATC CGT GAA TTC CAG CTT CCC AGT TCC CAG ATA AGC ATG GTG CCC AAT	342	
Ile Arg Glu Phe Gln Leu Pro Ser Ser Gln Ile Ser Met Val Pro Asn		
	60 65 70	
GTG GGC CTT AAG TTC TCC ATC AGC AAC GCC AAT ATC AAG ATC AGC GGC	390	
Val Gly Leu Lys Phe Ser Ile Ser Asn Ala Asn Ile Lys Ile Ser Gly		
	75 80 85	
AAA TGG AAG GCA CAA AAG AGA TTC TTA AAA ATG AGC GGC AAT TTT GAC	438	
Lys Trp Lys Ala Gln Lys Arg Phe Leu Lys Met Ser Gly Asn Phe Asp		
	90 95 100 105	
CTG AGC ATA GAA GGC ATG TCC ATT TCG GCT GAT CTG AAG CTG GGC AGT	486	
Leu Ser Ile Glu Gly Met Ser Ile Ser Ala Asp Leu Lys Leu Gly Ser		
	110 115 120	
AAC CCC ACG TCA GGC AAG CCC ACC ATC ACC TGC TCC AGC TGC AGC AGC	534	
Asn Pro Thr Ser Gly Lys Pro Thr Ile Thr Cys Ser Ser Cys Ser Ser		
	125 130 135	
CAC ATC AAC AGT GTC CAC GTG CAC ATC TCA AAG AGC AAA GTC GGG TGG	582	
His Ile Asn Ser Val His Val His Ile Ser Lys Ser Lys Val Gly Trp		
	140 145 150	
CTG ATC CAA CTC TTC CAC AAA AAA ATT GAG TCT GCG CTT CGA AAC AAG	630	
Leu Ile Gln Leu Phe His Lys Lys Ile Glu Ser Ala Leu Arg Asn Lys		
	155 160 165	

004201"60296960

ATG AAC AGC CAG GTC TGC GAG AAA GTG ACC AAT TCT GTA TCC TCC AAG	678
Met Asn Ser Gln Val Cys Glu Lys Val Thr Asn Ser Val Ser Ser Lys	
170 175 180 185	
CTG CAA CCT TAT TTC CAG ACT CTG CCA GTA ATG ACC AAA ATA GAT TCT	726
Leu Gln Pro Tyr Phe Gln Thr Leu Pro Val Met Thr Lys Ile Asp Ser	
190 195 200	
GTG GCT GGA ATC AAC TAT GGT CTG GTG GCA CCT CCA GCA ACC ACG GCT	774
Val Ala Gly Ile Asn Tyr Gly Leu Val Ala Pro Pro Ala Thr Thr Ala	
205 210 215	
GAG ACC CTG GAT GTA CAG ATG AAG GGG GAG TTT TAC AGT GAG AAC CAC	822
Glu Thr Leu Asp Val Gln Met Lys Gly Glu Phe Tyr Ser Glu Asn His	
220 225 230	
CAC AAT CCA CCT CCC TTT GCT CCA CCA GTG ATG GAG TTT CCC GCT GCC	870
His Asn Pro Pro Pro Phe Ala Pro Pro Val Met Glu Phe Pro Ala Ala	
235 240 245	
CAT GAC CGC ATG GTA TAC CTG GGC CTC TCA GAC TAC TTC TTC AAC ACA	918
His Asp Arg Met Val Tyr Leu Gly Leu Ser Asp Tyr Phe Phe Asn Thr	
250 255 260 265	
GCC GGG CTT GTA TAC CAA GAG GCT GGG GTC TTG AAG ATG ACC CTT AGA	966
Ala Gly Leu Val Tyr Gln Glu Ala Gly Val Leu Lys Met Thr Leu Arg	
270 275 280	
GAT GAC ATG ATT CCA AAG GAG TCC AAA TTT CGA CTG ACA ACC AAG TTC	1014
Asp Asp Met Ile Pro Lys Glu Ser Lys Phe Arg Leu Thr Thr Lys Phe	
285 290 295	
TTT GGA ACC TTC CTA CCT GAG GTG GCC AAG AAG TTT CCC AAC ATG AAG	1062
Phe Gly Thr Phe Leu Pro Glu Val Ala Lys Lys Phe Pro Asn Met Lys	
300 305 310	
ATA CAG ATC CAT GTC TCA GCC TCC ACC CCG CCA CAC CTG TCT GTG CAG	1110
Ile Gln Ile His Val Ser Ala Ser Thr Pro Pro His Leu Ser Val Gln	
315 320 325	
CCC ACC GGC CTT ACC TTC TAC CCT GCC GTG GAT GTC CAG GCC TTT GCC	1158
Pro Thr Gly Leu Thr Phe Tyr Pro Ala Val Asp Val Gln Ala Phe Ala	
330 335 340 345	
GTC CTC CCC AAC TCC TCC CTG GCT TCC CTC TTC CTG ATT GGC ATG CAC	1206
Val Leu Pro Asn Ser Ser Leu Ala Ser Leu Phe Leu Ile Gly Met His	
350 355 360	
ACA ACT GGT TCC ATG GAG GTC AGC GCC GAG TCC AAC AGG CTT GTT GGA	1254
Thr Thr Gly Ser Met Glu Val Ser Ala Glu Ser Asn Arg Leu Val Gly	
365 370 375	
GAG CTC AAG CTG GAT AGG CTG CTC CTG GAA CTG AAG CAC TCA AAT ATT	1302
Glu Leu Lys Leu Asp Arg Leu Leu Leu Glu Leu Lys His Ser Asn Ile	
380 385 390	
GGC CCC TTC CCG GTT GAA TTG CTG CAG GAT ATC ATG AAC TAC ATT GTA	1350
Gly Pro Phe Pro Val Glu Leu Leu Gln Asp Ile Met Asn Tyr Ile Val	
395 400 405	
CCC ATT CTT GTG CTG CCC AGG GTT AAC GAG AAA CTA CAG AAA GGC TTC	1398
Pro Ile Leu Val Leu Pro Arg Val Asn Glu Lys Leu Gln Lys Gly Phe	
410 415 420 425	

096596709 " 102400

CCT CTC CCG ACG CCG GCC AGA GTC CAG CTC TAC AAC GTA GTG CTT CAG	1446
Pro Leu Pro Thr Pro Ala Arg Val Gln Leu Tyr Asn Val Val Leu Gln	
430 435 440	
CCT CAC CAG AAC TTC CTG CTG TTC GGT GCA GAC GTT GTC TAT AAA	1491
Pro His Gln Asn Phe Leu Leu Phe Gly Ala Asp Val Val Tyr Lys	
445 450 455	
TGAAGGCACC AGGGGTGCCG GGGGCTGTCA GCCGCACCTG TTCCTGATGG GCTGTGGGGC	1551
ACCGGCTGCC TTTCCCCAGG GAATCCTCTC CAGATCTTAA CCAAGAGCCC CTTGCAAAC	1611
TCTTCGACTC AGATTCAGAA ATGATCTAAA CACGAGGAAA CATTATTCAT TGGAAAAGTG	1671
CATGGTGTGT ATTTTAGGGA TTATGAGCTT CTTTCAAGGG CTAAGGCTGC AGAGATATTT	1731
CCTCCAGGAA TCGTGTTCAT ATTGTAACCA AGAAATTTCC ATTTGTGCTT CATGAAAAAA	1791
AACTTCTGGT TTTTTCATG TG	1813

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 487 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Arg Glu Asn Met Ala Arg Gly Pro Cys Asn Ala Pro Arg Trp Val	
-31 -30 -25 -20	
Ser Leu Met Val Leu Val Ala Ile Gly Thr Ala Val Thr Ala Ala Val	
-15 -10 -5 1	
Asn Pro Gly Val Val Val Arg Ile Ser Gln Lys Gly Leu Asp Tyr Ala	
5 10 15	
Ser Gln Gln Gly Thr Ala Ala Leu Gln Lys Glu Leu Lys Arg Ile Lys	
20 25 30	
Ile Pro Asp Tyr Ser Asp Ser Phe Lys Ile Lys His Leu Gly Lys Gly	
35 40 45	
His Tyr Ser Phe Tyr Ser Met Asp Ile Arg Glu Phe Gln Leu Pro Ser	
50 55 60 65	
Ser Gln Ile Ser Met Val Pro Asn Val Gly Leu Lys Phe Ser Ile Ser	
70 75 80	
Asn Ala Asn Ile Lys Ile Ser Gly Lys Trp Lys Ala Gln Lys Arg Phe	
85 90 95	
Leu Lys Met Ser Gly Asn Phe Asp Leu Ser Ile Glu Gly Met Ser Ile	
100 105 110	
Ser Ala Asp Leu Lys Leu Gly Ser Asn Pro Thr Ser Gly Lys Pro Thr	
115 120 125	
Ile Thr Cys Ser Ser Cys Ser Ser His Ile Asn Ser Val His Val His	

004207" 60/96960

130		135		140		145
Ile Ser Lys Ser Lys Val Gly Trp Leu Ile Gln Leu Phe His Lys Lys						
		150		155		160
Ile Glu Ser Ala Leu Arg Asn Lys Met Asn Ser Gln Val Cys Glu Lys						
		165		170		175
Val Thr Asn Ser Val Ser Ser Lys Leu Gln Pro Tyr Phe Gln Thr Leu						
		180		185		190
Pro Val Met Thr Lys Ile Asp Ser Val Ala Gly Ile Asn Tyr Gly Leu						
		195		200		205
Val Ala Pro Pro Ala Thr Thr Ala Glu Thr Leu Asp Val Gln Met Lys						
		210		215		220
Gly Glu Phe Tyr Ser Glu Asn His His Asn Pro Pro Pro Phe Ala Pro						
		230		235		240
Pro Val Met Glu Phe Pro Ala Ala His Asp Arg Met Val Tyr Leu Gly						
		245		250		255
Leu Ser Asp Tyr Phe Phe Asn Thr Ala Gly Leu Val Tyr Gln Glu Ala						
		260		265		270
Gly Val Leu Lys Met Thr Leu Arg Asp Asp Met Ile Pro Lys Glu Ser						
		275		280		285
Lys Phe Arg Leu Thr Thr Lys Phe Phe Gly Thr Phe Leu Pro Glu Val						
		290		295		300
Ala Lys Lys Phe Pro Asn Met Lys Ile Gln Ile His Val Ser Ala Ser						
		310		315		320
Thr Pro Pro His Leu Ser Val Gln Pro Thr Gly Leu Thr Phe Tyr Pro						
		325		330		335
Ala Val Asp Val Gln Ala Phe Ala Val Leu Pro Asn Ser Ser Leu Ala						
		340		345		350
Ser Leu Phe Leu Ile Gly Met His Thr Thr Gly Ser Met Glu Val Ser						
		355		360		365
Ala Glu Ser Asn Arg Leu Val Gly Glu Leu Lys Leu Asp Arg Leu Leu						
		370		375		380
Leu Glu Leu Lys His Ser Asn Ile Gly Pro Phe Pro Val Glu Leu Leu						
		390		395		400
Gln Asp Ile Met Asn Tyr Ile Val Pro Ile Leu Val Leu Pro Arg Val						
		405		410		415
Asn Glu Lys Leu Gln Lys Gly Phe Pro Leu Pro Thr Pro Ala Arg Val						
		420		425		430
Gln Leu Tyr Asn Val Val Leu Gln Pro His Gln Asn Phe Leu Leu Phe						
		435		440		445
Gly Ala Asp Val Val Tyr Lys						
		450		455		

09696709 " 102400

WHAT IS CLAIMED ARE:

1. In a therapeutic composition comprising a BPI protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improved composition comprising a bactericidal-activity-enhancing poloxamer surfactant.
2. The therapeutic composition of claim 1 further comprising EDTA.
3. The improved composition of claim 1 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.
4. The therapeutic composition of claim 3 further comprising EDTA.
5. In a method for treating a bacterial infection comprising administering a composition of BPI protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improvement comprising administering a therapeutic composition of BPI protein product and bactericidal-activity-enhancing poloxamer surfactant.
6. The improved method of claim 5 wherein the therapeutic composition further comprises EDTA.
7. The improved method of claim 5 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

09696709 102400

8. The improved method of claim 5 further comprising administering an antibiotic.

9. A composition for inhibiting bacterial and fungal growth comprising a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.

10. The composition of claim 9 further comprising EDTA.

11. The composition of claim 9 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

12. A method for inhibiting bacterial and fungal growth comprising treating the bacteria or fungus with a composition of a BPI protein product and a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant.

13. The method of claim 12 wherein the composition further comprises EDTA.

14. The method of claim 12 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

004207 160796960

ABSTRACT

Improved therapeutic compositions having enhanced anti-microbial activity comprising a bactericidal/permeability-increasing (BPI) protein product and an bactericidal-activity enhancing polyoxyethylene block copolymer surfactant (poloxamer) surfactant or a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant, optionally with EDTA, and methods for treating bacterial infection by administering such compositions, alone or concurrently with antibiotics.

004207 60496960

DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "IMPROVED PHARMACEUTICAL COMPOSITIONS COMPRISING BACTERICIDAL/PERMEABILITY-INCREASING (BPI) PROTEIN PRODUCTS," the specification of which was filed on January 12, 1996 as Application Serial No. 08/586,133; it was filed as PCT International Application No. PCT/US96/01095 on January 16, 1996 and was amended under Article 19 on _____ (if applicable). I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

(Application Serial Number)	(Country)	(Day/Month/Year Filed)	Priority Claimed	
			<input type="checkbox"/> Yes	<input type="checkbox"/> No
			<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below:

(Application Serial Number)	(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in 37 C.F.R. §1.56 which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

(Application Serial Number)	(Day/Month/Year Filed)	(Status-Patented, Pending or Abandoned)
08/530,599	19 September 1995	Pending
08/372,104	13 January, 1995	Pending

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I hereby appoint as my attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Janet M. McNicholas (32,918) of McAndrews, Held & Malloy, Ltd., 500 West Madison Street, 34th Floor, Chicago, IL 60661

Michael F. Borun (25,447) and Jeffrey S. Sharp (31,379) of Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606

Send correspondence to: Janet M. McNicholas, Esq.

FIRM NAME	PHONE NO.	STREET	CITY & STATE	ZIP CODE
McAndrews, Held & Malloy, Ltd.	312-707-8889	500 West Madison Street 34th Floor	Chicago, Illinois	60661

Full Name of First or Sole Inventor	Citizenship
Lewis H. Lambert, Jr.	United States of America
Residence Address - Street	Post Office Address - Street
45928 Omega Drive	
City (Zip)	City (Zip)
Fremont 94539	
State or Country	State or Country
California	
Date	Signature
3/26/96	<i>Lewis H. Lambert, Jr.</i>

See second page for additional inventor(s)

See reverse for relevant rules & statutes

004207" 60296960

APPLICABLE RULES AND STATUTES

37 CFR 1.56. DUTY OF DISCLOSURE - INFORMATION MATERIAL TO PATENTABILITY (Applicable Portion)

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is canceled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is canceled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§ 1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentability defines, to make sure that any material information contained therein is disclosed to the Office.

Information relating to the following factual situations enumerated in 35 USC 102 and 103 may be considered material under 37 CFR 1.56(a).

35 U.S.C. 102. CONDITIONS FOR PATENTABILITY: NOVELTY AND LOSS OF RIGHT TO PATENT

A person shall be entitled to a patent unless --

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for patent, or
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of the application for patent in the United States, or
- (c) he has abandoned the invention, or
- (d) the invention was first patented or caused to be patented, or was the subject of an inventor's certificate, by the applicant or his legal representatives or assigns in a foreign country prior to the date of the application for patent in this country on an application for patent or inventor's certificate filed more than twelve months before the filing of the application in the United States, or
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraph (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent, or
- (f) he did not himself invent the subject matter sought to be patented, or
- (g) before the applicant's invention thereof the invention was made in this country by another who had not abandoned, suppressed, or concealed it. In determining priority of invention there shall be considered not only the respective dates of conception and reduction to practice of the invention, but also the reasonable diligence of one who was first to conceive and last to reduce to practice, from a time prior to conception by the other.

35 U.S.C. 103. CONDITIONS FOR PATENTABILITY: NON-OBVIOUS SUBJECT MATTER

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

35 U.S.C. 112. SPECIFICATION (Applicable Portion)

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

004207 6029560

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Lewis H. Lambert, Jr.

Serial No.: to be assigned

Filed: Herewith


For: IMPROVED THERAPEUTIC
COMPOSITIONS COMPRISING
BACTERICIDAL/PERMEABILITY-
INCREASING (BPI) PROTEIN
PRODUCTS

Art Unit: to be assigned

Examiner: to be assigned

) **CERTIFICATE OF MAILING UNDER**
) **37 CFR §1.10**
)

) I hereby certify that this
) correspondence is being deposited with
) the United States Postal Service on
) **October 24, 2000**, in an envelope,
) postage prepaid, addressed to Box Patent
) Application, Assistant Commissioner for
) Patents, Washington, D.C. 20231
) utilizing the "Express Mail Post Office to
) Addressee" service of the United States
) Postal Service under Mailing Label No.
) EL542916975US.
)

) 
) Sonji Shivers
)

**REQUEST TO USE COMPUTER READABLE
FORM FROM ANOTHER APPLICATION**

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Applicant requests entry of the identical computer readable form from a related application. Specifically, the computer-readable form of the Sequence Listing in the above-identified application is identical to that in Application Serial No. 08/586,133, filed January 12, 1996. In accordance with 37 C.F.R. §1.821(e), please use the only computer-readable form of the Sequence Listing filed in that application as the computer-readable form in the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer-readable form of the Sequence

Listing that will be used in the instant application. A paper copy of the sequence listing is included in the originally-filed specification of the instant application.

Respectfully submitted,

October 24, 2000


Janet M. McNicholas, Ph.D.
Reg. No. 32,918

McANDREWS, HELD & MALLOY, Ltd.
500 W. Madison Street, 34th Floor
Chicago, Illinois 60661
(312) 775-8000